<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease - Chung, EYM - 2020 | Cochrane Library</title> <meta content="Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease - Chung, EYM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007004.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease - Chung, EYM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007004.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007004.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease" name="citation_title"/> <meta content="Edmund YM Chung" name="citation_author"/> <meta content="Royal North Shore Hospital" name="citation_author_institution"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Davide Bolignano" name="citation_author"/> <meta content="CNR - Italian National Council of Research" name="citation_author_institution"/> <meta content="Sankar D Navaneethan" name="citation_author"/> <meta content="Baylor College of Medicine" name="citation_author_institution"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="giovanni.strippoli@uniba.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007004.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007004.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007004.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007004.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiotensin Receptor Antagonists [*therapeutic use]; Angiotensin-Converting Enzyme Inhibitors [*therapeutic use]; Bias; Calcium Channel Blockers [therapeutic use]; Canrenone [therapeutic use]; Disease Progression; Eplerenone [therapeutic use]; Hyperkalemia [chemically induced, prevention &amp; control]; Kidney Failure, Chronic [*drug therapy]; Mineralocorticoid Receptor Antagonists [adverse effects, *therapeutic use]; Naphthyridines [therapeutic use]; Proteinuria [*drug therapy]; Randomized Controlled Trials as Topic; Spironolactone [adverse effects, analogs &amp; derivatives, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007004.pub4&amp;doi=10.1002/14651858.CD007004.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007004\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007004\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007004.pub4",title:"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease",firstPublishedDate:"Oct 27, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007004.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007004.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007004.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007004.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007004.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007004.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007004.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007004.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007004.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007004.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6886 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007004.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0127"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-sec-0121"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/appendices#CD007004-sec-0132"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/table_n/CD007004StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/table_n/CD007004StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0004">Edmund YM Chung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0005">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0006">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0007">Davide Bolignano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0008">Sankar D Navaneethan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0009">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information#CD007004-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information/en#CD007004-sec-0138">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007004.pub4">https://doi.org/10.1002/14651858.CD007004.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007004-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007004-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007004-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007004-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007004-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007004-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007004-abs-0001" lang="en"> <section id="CD007004-sec-0001"> <h3 class="title" id="CD007004-sec-0001">Background</h3> <p>Treatment with angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). However, resolution of proteinuria may be incomplete with these therapies and the addition of an aldosterone antagonist may be added to further prevent progression of CKD. This is an update of a Cochrane review first published in 2009 and updated in 2014. </p> </section> <section id="CD007004-sec-0002"> <h3 class="title" id="CD007004-sec-0002">Objectives</h3> <p>To evaluate the effects of aldosterone antagonists (selective (eplerenone), non‐selective (spironolactone or canrenone), or non‐steroidal mineralocorticoid antagonists (finerenone)) in adults who have CKD with proteinuria (nephrotic and non‐nephrotic range) on: patient‐centred endpoints including kidney failure (previously know as end‐stage kidney disease (ESKD)), major cardiovascular events, and death (any cause); kidney function (proteinuria, estimated glomerular filtration rate (eGFR), and doubling of serum creatinine); blood pressure; and adverse events (including hyperkalaemia, acute kidney injury, and gynaecomastia). </p> </section> <section id="CD007004-sec-0003"> <h3 class="title" id="CD007004-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 13 January 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD007004-sec-0004"> <h3 class="title" id="CD007004-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared aldosterone antagonists in combination with ACEi or ARB (or both) to other anti‐hypertensive strategies or placebo in participants with proteinuric CKD. </p> </section> <section id="CD007004-sec-0005"> <h3 class="title" id="CD007004-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study quality and extracted data. Data were summarised using random effects meta‐analysis. We expressed summary treatment estimates as a risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) when different scales were used together with their 95% confidence interval (CI). Risk of bias were assessed using the Cochrane tool. Evidence certainty was evaluated using GRADE. </p> </section> <section id="CD007004-sec-0006"> <h3 class="title" id="CD007004-sec-0006">Main results</h3> <p>Forty‐four studies (5745 participants) were included. Risk of bias in the evaluated methodological domains were unclear or high risk in most studies. Adequate random sequence generation was present in 12 studies, allocation concealment in five studies, blinding of participant and investigators in 18 studies, blinding of outcome assessment in 15 studies, and complete outcome reporting in 24 studies. </p> <p>All studies comparing aldosterone antagonists to placebo or standard care were used in addition to an ACEi or ARB (or both). None of the studies were powered to detect differences in patient‐level outcomes including kidney failure, major cardiovascular events or death. </p> <p>Aldosterone antagonists had uncertain effects on kidney failure (2 studies, 84 participants: RR 3.00, 95% CI 0.33 to 27.65, I² = 0%; <i>very low certainty evidence</i> ), death (3 studies, 421 participants: RR 0.58, 95% CI 0.10 to 3.50, I² = 0%; <i>low certainty evidence</i> ), and cardiovascular events (3 studies, 1067 participants: RR 0.95, 95% CI 0.26 to 3.56; I² = 42%; <i>low certainty evidence</i> ) compared to placebo or standard care. Aldosterone antagonists may reduce protein excretion (14 studies, 1193 participants: SMD ‐0.51, 95% CI ‐0.82 to ‐0.20, I² = 82%; <i>very low certainty evidence</i> ), eGFR (13 studies, 1165 participants, MD ‐3.00 mL/min/1.73 m², 95% CI ‐5.51 to ‐0.49, I² = 0%, <i>low certainty evidence</i> ) and systolic blood pressure (14 studies, 911 participants: MD ‐4.98 mmHg, 95% CI ‐8.22 to ‐1.75, I² = 87%; <i>very low certainty evidence</i>) compared to placebo or standard care. </p> <p>Aldosterone antagonists probably increase the risk of hyperkalaemia (17 studies, 3001 participants: RR 2.17, 95% CI 1.47 to 3.22, I² = 0%; <i>moderate certainty evidence</i> ), acute kidney injury (5 studies, 1446 participants: RR 2.04, 95% CI 1.05 to 3.97, I² = 0%; <i>moderate certainty evidence</i> ), and gynaecomastia (4 studies, 281 participants: RR 5.14, 95% CI 1.14 to 23.23, I² = 0%; <i>moderate certainty evidence</i>) compared to placebo or standard care. </p> <p>Non‐selective aldosterone antagonists plus ACEi or ARB had uncertain effects on protein excretion (2 studies, 139 participants: SMD ‐1.59, 95% CI ‐3.80 to 0.62, I² = 93%; <i>very low certainty evidence</i> ) but may increase serum potassium (2 studies, 121 participants: MD 0.31 mEq/L, 95% CI 0.17 to 0.45, I² = 0%; <i>low certainty evidence</i> ) compared to diuretics plus ACEi or ARB. Selective aldosterone antagonists may increase the risk of hyperkalaemia (2 studies, 500 participants: RR 1.62, 95% CI 0.66 to 3.95, I² = 0%; <i>low certainty evidence</i>) compared ACEi or ARB (or both). There were insufficient studies to perform meta‐analyses for the comparison between non‐selective aldosterone antagonists and calcium channel blockers, selective aldosterone antagonists plus ACEi or ARB (or both) and nitrate plus ACEi or ARB (or both), and non‐steroidal mineralocorticoid antagonists and selective aldosterone antagonists. </p> </section> <section id="CD007004-sec-0007"> <h3 class="title" id="CD007004-sec-0007">Authors' conclusions</h3> <p>The effects of aldosterone antagonists when added to ACEi or ARB (or both) on the risks of death, major cardiovascular events, and kidney failure in people with proteinuric CKD are uncertain. Aldosterone antagonists may reduce proteinuria, eGFR, and systolic blood pressure in adults who have mild to moderate CKD but may increase the risk of hyperkalaemia, acute kidney injury and gynaecomastia when added to ACEi and/or ARB. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007004-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007004-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007004-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007004-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007004-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007004-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007004-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007004-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007004-abs-0002" lang="en"> <h3>Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease </h3> <p><b>What is the issue?</b> </p> <p>People who have chronic kidney disease (CKD) have a higher risk of heart disease and declining kidney function. Increased amounts of protein in the urine is a sign of kidney stress and is linked to declining kidney function. Medications used to lower blood pressure and reduce protein levels in the urine ‐ in particular, angiotensin‐converting enzyme Inhibitors (ACEi) and angiotensin receptor blockers (ARBs) ‐remain the core treatment to prevent the declining of kidney function in CKD. </p> <p>Protecting kidney function with these medications may however be incomplete and adding an aldosterone antagonist (blocker) (for example, spironolactone, canrenone, eplerenone, or finerenone) may better protect kidney function in the long‐term. By blocking the production of aldosterone, the kidneys excrete more water which can lead to a lowering of blood pressure. However, they can cause side effects including enlargement of male breast tissue, and when used with ACEi or ARBs may cause high levels of potassium in the blood or a decline in kidney function. </p> <p><b>What did we do?</b> We reviewed the available studies looking at the addition of aldosterone blockers to standard treatment in people with CKD to see if they slowed the decline of kidney function and the subsequent need for dialysis or a kidney transplant. We looked at whether they reduced heart disease, the amount of protein in urine, or improved blood pressure. We also looked at whether aldosterone blockers were safe in terms of risks of male breast enlargement, potassium levels in the blood, and short‐term effects on kidney function. </p> <p><b>What did we find?</b> We found that adding aldosterone blockers to a patient's current medications (ACEi or ARBs), lowered both protein in the urine and systolic blood pressure. Kidney function declined, however the effects on survival were uncertain. The addition of aldosterone blockers increased the amount of potassium in the blood. This may require medication changes, extra blood tests, and may be potentially harmful. Treatment with aldosterone blockers also increased the chance of short‐term decline in kidney function and enlargement of male breast tissue. </p> <p><b>Conclusions</b> It is unclear as to whether aldosterone blockers protect kidney function or prevent heart disease in people who have CKD. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007004-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007004-sec-0127"></div> <h3 class="title" id="CD007004-sec-0128">Implications for practice</h3> <section id="CD007004-sec-0128"> <p>In adults with CKD who have an eGFR between 15 and 90 mL/min/1.73 m² and who have persistent proteinuria despite being on maximal doses of ACEi or ARB, aldosterone antagonists may reduce proteinuria, eGFR and systolic blood pressure. However, treatment effects on patient‐relevant outcomes including progression to kidney failure, major cardiovascular events, and death are uncertain. Treatment using aldosterone antagonists in combination with ACEi or ARB (or both) may increase risk of hyperkalaemia and probably increases risk of acute kidney injury. Treatment using spironolactone probably increases risk of gynaecomastia. Evidence for the efficacy and safety of aldosterone antagonists compared to other interventions (diuretics, calcium channel blockers, nitrates, or ACEI or ARB (or both)) and evidence for the relative efficacy between different aldosterone antagonists are sparse. Patients and clinicians may reasonably choose not to use an aldosterone antagonist due to the uncertain benefits of treatment and identified risks of harm and adverse events. </p> </section> <h3 class="title" id="CD007004-sec-0129">Implications for research</h3> <section id="CD007004-sec-0129"> <p>Existing evidence on the effect of aldosterone antagonists on progression of CKD, cardiovascular events and death are uncertain. Whilst there is strong evidence supporting the association between reduction of proteinuria with ACEi or ARB and reduced risk of kidney failure, data supporting the benefit of further reduction in proteinuria using aldosterone antagonists in addition to ACEi or ARB on risk of kidney failure are lacking. Clinical evidence for the cardioprotective benefits of aldosterone antagonists in addition to ACEi or ARB is also sparse. Therefore, future high‐quality studies with adequate follow‐up that are powered to detect differences kidney failure and major cardiovascular events are necessary. The concurrent use of potassium‐binding agents such as patiromer may reduce the risk of hyperkalaemia associated with aldosterone antagonists (<a href="./references#CD007004-bbs2-0080" title="AgarwalR , RossignolP , RomeroA , GarzaD , MayoMR , WarrenS , et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet2019;394(10208):1540–50. [MEDLINE: 31533906]">AMBER 2019</a>) though whether this will lead to improvements in long‐term patient‐level outcomes requires further study. Two ongoing studies of finerenone (<a href="./references#CD007004-bbs2-0075" title="BakrisGL , AgarwalR , AnkerSD , PittB , RuilopeLM , NowackC , et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. American Journal of Nephrology2019;50(5):333-44. [MEDLINE: 31655812]">FIDELIO‐DKD 2019</a>; <a href="./references#CD007004-bbs2-0076" title="RuilopeLM , AgarwalR , AnkerSD , BakrisGL , FilippatosG , NowackC , et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. American Journal of Nephrology2019;50(5):345-56. [MEDLINE: 31665733]">FIGARO‐DKD 2019</a>) will provide important insights into whether non‐steroidal mineralocorticoid antagonists in addition to ACEi or ARB may reduce the risk of patient‐level cardiovascular and kidney endpoints without increasing the risk of hyperkalaemia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007004-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007004-sec-0008"></div> <div class="table" id="CD007004-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aldosterone antagonists versus placebo or standard care for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus placebo or standard care for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> placebo or standard care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or standard care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.33 to 27.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1,000<br/>(37 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.17<br/>(1.47 to 3.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3001 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000<br/>(1 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.10 to 3.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000<br/>(8 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/>(0.26 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1067 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doubling serum creatinine</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1,000<br/>(57 to 202) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.30<br/>(0.69 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AKI</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1,000<br/>(31 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.04<br/>(1.05 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1446 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD was 0.51 lower with aldosterone antagonists (0.82 lower to 0.20 lower) than placebo or standard care </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1193 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>7, 8, 9, 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR (mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 3.00 mL/min/1.73 m² lower with aldosterone antagonists (5.51 lower to 0.49 lower) than placebo or standard care </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study and complete outcome data in no studies </p> <p><sup>2</sup> Treatment estimate had a wide CI </p> <p><sup>3</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in three studies, blinding of outcome assessment in seven studies, complete outcome data in 11 studies </p> <p><sup>4</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in one study, and complete outcome data in one study </p> <p><sup>5</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in one study, complete outcome data in one study </p> <p><sup>6</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in three studies, complete outcome data in one study </p> <p><sup>7</sup> Evidence quality was downgraded because of suspected small study effects from asymmetry on inverted funnel plot </p> <p><sup>8</sup>Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in seven studies, complete outcome data in nine studies </p> <p><sup>9</sup> There was significant heterogeneity between studies </p> <p><sup>10</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> <p><sup>11</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in four studies, complete outcome data in six studies </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007004-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aldosterone antagonists versus diuretics for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus diuretics for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> diuretics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with diuretics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD was 1.59 lower (3.8 lower to 0.62 higher) with aldosterone antagonists than diuretics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 2, 3, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 2 mL/min/1.73 m² higher with aldosterone antagonists (26.31 lower to 30.31 higher) than diuretics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded due to study risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete data in one study </p> <p><sup>2</sup> There was significant heterogeneity between the studies </p> <p><sup>3</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> <p><sup>4</sup> Treatment estimate had a wide confidence interval </p> <p><sup>5</sup> Single study with unclear allocation concealment </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007004-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Aldosterone antagonists versus calcium channel blockers for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonists versus calcium channel blocker for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> calcium channel blocker </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with calcium channel blocker</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not to be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study with unclear allocation concealment </p> <p><sup>2</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007004-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> ACEi or ACEi plus ARB </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ACEi or ACEi plus ARB</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000<br/>(24 to 146) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.62<br/>(0.66 to 3.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3, 4, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6, 7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACEi:</b> angiotensin‐converting enzyme inhibitors; <b>ARB:</b> angiotensin receptor blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded due to risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete outcome data in one study </p> <p><sup>2</sup> Treatment estimates had wide confidence intervals </p> <p><sup>3</sup> Evidence quality was downgraded due to risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete outcome data in two studies </p> <p><sup>4</sup> Evidence quality was downgraded as proteinuria is a surrogate outcome for CKD progression </p> <p><sup>5</sup> Raw data was not available in studies to allow pooling of treatment estimates </p> <p><sup>6</sup> Single study with unclear allocation concealment </p> <p><sup>7</sup> Insufficient studies to inform precision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007004-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> nitrate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with nitrate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study with unclear allocation concealment and unclear blinding of outcome assessment </p> <p><sup>2</sup> Evidence quality was downgraded as proteinuria is a surrogate outcome for CKD progression </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007004-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> non‐steroidal mineralocorticoid receptor antagonist<br/><b>Comparison:</b> selective aldosterone antagonist </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with selective aldosterone antagonist</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐steroidal mineralocorticoid receptor antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/>(21 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.45 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1023 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/>(11 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.31 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1055 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doubling serum creatinine</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/834</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/221**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80<br/>(0.03 to 19.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1055 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteinuria</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the non‐steroidal mineralocorticoid receptor antagonist group<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study </p> <p><sup>2</sup> Treatment estimate had a wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007004-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007004-sec-0009"></div> <section id="CD007004-sec-0010"> <h3 class="title" id="CD007004-sec-0010">Description of the condition</h3> <p>Chronic kidney disease (CKD) has a global prevalence of 10% to 12% and progression to kidney failure (previously known as end‐stage kidney disease (ESKD)) is rising due to the global diabetes and hypertension pandemics (<a href="./references#CD007004-bbs2-0103" title="MillsKT , XuY , ZhangW , BundyJD , ChenCS , KellyTN , et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney International2015;88(5):950-7. [MEDLINE: 26221752]">Mills 2015</a>; <a href="./references#CD007004-bbs2-0106" title="NugentRA , FathimaSF , FeiglAB , ChyungD . The burden of chronic kidney disease on developing nations: s 21st century challenge in global health. Nephron Clinical Practice2011;118(3):c269–277. [MEDLINE: 21212690]">Nugent 2011</a>). There is a significant associated economic burden to patients, caregivers, and society, which increases throughout disease progression (<a href="./references#CD007004-bbs2-0126" title="WangV , VilmeH , MaciejewskiML , BoulwareLE . The economic burden of chronic kidney disease and end-stage renal disease. Seminars in Nephrology2016;36(4):319-30. [MEDLINE: 27475662]">Wang 2016</a>). Angiotensin‐converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) are the standard of care to slow progression of CKD and reduce incidence of kidney failure in patients with proteinuria irrespective of primary kidney disease (<a href="./references#CD007004-bbs2-0098" title="JafarTH , SchmidCH , LandaM , GiatrasI , TotoR , RemuzziG , et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine2001;135(2):73-87. [MEDLINE: 11453706]">Jafar 2001</a>; <a href="./references#CD007004-bbs2-0122" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>) because they lower proteinuria and blood pressure, which are both independent predictors of death in adults with CKD (<a href="./references#CD007004-bbs2-0083" title="BrennerBM , CooperME , deZeeuwD , KeaneWF , MitchWE , ParvingHH , et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine2001;345(12):861-9. [MEDLINE: 11565518]">Brenner 2001</a>; <a href="./references#CD007004-bbs2-0087" title="Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet1997;349(9069):1857-63. [MEDLINE: 9217756]">GISEN 1997</a>; <a href="./references#CD007004-bbs2-0101" title="MathiesenER , HommelE , HansenHP , SmidtUM , ParvingHH . Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ1999;319(7201):24-5. [MEDLINE: 10390455]">Mathiesen 1999</a>). However, ACEi or ARB slow, but may not completely retard, the progression of CKD (<a href="./references#CD007004-bbs2-0114" title="SchieppatiA , RemuzziG . The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney International2003;64(6):1947-55. [MEDLINE: 14633117]">Schieppati 2003</a>). </p> </section> <section id="CD007004-sec-0011"> <h3 class="title" id="CD007004-sec-0011">Description of the intervention</h3> <p>Animal studies have shown that aldosterone has an independent role in the development of hypertensive kidney disease and vascular injury resulting in myocardial and renal fibrosis (<a href="#CD007004-fig-0001">Figure 1</a>), and exacerbates glomerulosclerosis resulting in severe proteinuria (<a href="./references#CD007004-bbs2-0081" title="BombackAS , KlemmerPJ . The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology2007;3(9):486-92. [MEDLINE: 17717561]">Bomback 2007</a>), which is reduced with aldosterone blockade (<a href="./references#CD007004-bbs2-0079" title="AldigierJC , KanjanbuchT , MaLJ , BrownNJ , FogoAB . Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the American Society of Nephrology2005;16(11):3306-14. [MEDLINE: 16192423]">Aldigier 2005</a>; <a href="./references#CD007004-bbs2-0090" title="GreeneEL , KrenS , HostetterTH . Role of aldosterone in the remnant kidney model in the rat. Journal of Clinical Investigation1996;98(4):1063-8. [MEDLINE: 8770880]">Green 1996</a>; <a href="./references#CD007004-bbs2-0113" title="RochaR , ChanderPN , KhannaK , ZuckermanA , Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension1998;31(1 Pt 2):451-8. [MEDLINE: 9453344]">Rocha 1998</a>; <a href="./references#CD007004-bbs2-0117" title="SilvestreJS , RobertV , HeymesC , Aupetit-FaisantB , MouasC , MoalicJM , et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry1998;273(9):4883-91. [MEDLINE: 9478930]">Silvestre 1998</a>). Renin‐angiotensin‐aldosterone system blockade with ACEi or ARB result in incomplete suppression of serum aldosterone levels and is known as the 'aldosterone escape phenomenon' (<a href="./references#CD007004-bbs2-0120" title="StaessenJ , LijnenP , FagardR , VerschuerenLJ , AmeryA . Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology1981;91(3):457-65. [MEDLINE: 7035596]">Staessen 1981</a>). Further experimental studies have established this theory and in humans, the treatment of adults with CKD exhibiting aldosterone escape phenomenon with aldosterone antagonists reduces proteinuria (<a href="./references#CD007004-bbs2-0086" title="Fritsch NevesM , SchiffrinEL . Aldosterone: a risk factor for vascular disease. Current Hypertension Reports2003;5(1):59-65. [MEDLINE: 12530937]">Fritsch Neves 2003</a>). However, aldosterone antagonism may increase risks of hyperkalaemia and gynaecomastia (<a href="./references#CD007004-bbs2-0105" title="NappiJM ,  SiegA . Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vascular Health &amp; Risk Management2011;7:353-63. [MEDLINE: 21731887]">Nappi 2011</a>). Novel non‐steroidal mineralocorticoid receptor antagonists such as finerenone are more selective for the mineralocorticoid receptor than other steroid receptors including the glucocorticoid receptor, androgen receptor and progesterone receptor (<a href="./references#CD007004-bbs2-0082" title="BramlageP , SwiftSL , ThoenesM , MinguetJ , FerreroC , SchmiederRE . Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. European Journal of Heart Failure2016;18(1):28-37. [MEDLINE: 26634965]">Bramlage 2016</a>) and may provide similar efficacy as non‐selective aldosterone antagonist but improved safety profile. </p> <div class="figure" id="CD007004-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Mechanisms of cardiac and kidney damage induced by aldosterone excess" data-id="CD007004-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Mechanisms of cardiac and kidney damage induced by aldosterone excess</p> </div> </div> </div> </section> <section id="CD007004-sec-0012"> <h3 class="title" id="CD007004-sec-0012">How the intervention might work</h3> <p>Multiple aldosterone‐mediated mechanisms have been shown to contribute to renal vascular injury and fibrosis in animal studies. These include aldosterone‐mediated increases in plasminogen activator inhibitor‐1 (PAI‐1) which inhibits the fibrinolytic system and activates latent growth factors; up‐regulation of transforming growth factor‐b and associated fibroblast differentiation, up‐regulation of collagen synthesis and down regulation of matrix metalloproteinase collagenase; generation of oxygen‐free radicals and hydrogen peroxide; and up regulation of endothelin‐1 with resultant vasoconstriction (<a href="./references#CD007004-bbs2-0093" title="HollenbergNK . Aldosterone in the development and progression of renal injury. Kidney International2004;66(1):1-9. [MEDLINE: 15200407]">Hollenberg 2004</a>). However, a common pathway is yet to be clearly defined. In a rat model, renal radiation injury resulted in an eight‐fold increase in the expression of PAI‐1 messenger RNA (mRNA) and non‐selective aldosterone blockade (spironolactone) significantly decreased PAI‐1 mRNA expression, development of glomerulosclerosis and proteinuria (<a href="./references#CD007004-bbs2-0084" title="BrownNJ , NakamuraS , MaL , NakamuraI , DonnertE , FreemanM , et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney International2000;58(3):1219-27. [MEDLINE: 10972684]">Brown 2000</a>). In human studies, beneficial effects of aldosterone blockade (non‐selective and selective) have been established in congestive cardiac failure (<a href="./references#CD007004-bbs2-0094" title="HostetterTH , IbrahimHN . Aldosterone in chronic kidney and cardiac disease. Journal of the American Society of Nephrology2003;14(9):2395-401. [MEDLINE: 12937319]">Hostetter 2003</a>; <a href="./references#CD007004-bbs2-0108" title="PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709-17. [MEDLINE: 10471456]">Pitt 1999</a>; <a href="./references#CD007004-bbs2-0109" title="PittB , RemmeW , ZannadF , NeatonJ , MartinezF , RonikerB , et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.[Erratum in: N Engl J Med. 2003 May 29;348(22):2271]. New England Journal of Medicine2003;348(14):1309-21. [MEDLINE: 12668699]">Pitt 2003</a>) and proteinuric CKD (<a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>). In animal studies, finerenone had a more potent natriuretic response than eplerenone but no impact on urinary potassium levels (<a href="./references#CD007004-bbs2-0099" title="KolkhofP , DelbeckM , KretschmerA , SteinkeW , HartmannE , BärfackerL , et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Journal of Cardiovascular Pharmacology2014;64(1):69-78. [MEDLINE: 24621652]">Kolkhof 2014</a>). Therefore, it is hypothesised that non‐steroidal mineralocorticoid receptor antagonists will exhibit the benefits of aldosterone blockade without the risk of hyperkalaemia. </p> </section> <section id="CD007004-sec-0013"> <h3 class="title" id="CD007004-sec-0013">Why it is important to do this review</h3> <p>Aldosterone blockade in combination with ACEi or ARB may reduce proteinuria but their effects on patient‐level outcomes such as kidney failure requiring dialysis or kidney transplantation or major cardiovascular events and their safety in regards to risk of hyperkalaemia and acute kidney injury, particularly in adults who have coexisting CKD, remain uncertain. Thus, we analysed the benefits and harms of aldosterone antagonists in adults who had CKD and who were or who were not already treated with ACEi or ARB (or in combination). We specifically focused on treatment effects for patient‐level outcomes including kidney failure and major cardiovascular events, proteinuria, and kidney function. New relevant studies on CKD patients receiving aldosterone antagonists, including non‐steroidal mineralocorticoid antagonists, have recently been completed and their inclusion to update the previous published versions of this review (<a href="./references#CD007004-bbs2-0127" title="BolignanoD , PalmerSC , NavaneethanSD , StrippoliGF . Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews2014, Issue 4. Art. No: CD007004. [DOI: 10.1002/14651858.CD007004.pub3]">Bolignano 2014</a>; <a href="./references#CD007004-bbs2-0129" title="NavaneethanSD , NigwekarSU , SehgalAR , StrippoliGF . Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clinical Journal of The American Society of Nephrology: CJASN2009;4(3):542-51. [MEDLINE: 19261819]">Navaneethan 2009</a>) would be valuable. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007004-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007004-sec-0014"></div> <p>To evaluate the effect of aldosterone antagonists (selective (eplerenone), non‐selective (spironolactone), and non‐steroidal (finerenone)) in combination with ACEi or ARB in adults who have CKD with proteinuria (nephrotic and non‐nephrotic range) on: </p> <p> <ul id="CD007004-list-0001"> <li> <p>Patient‐centred endpoints including kidney failure, major cardiovascular events, and death (any cause) </p> </li> <li> <p>Kidney function (proteinuria, estimated glomerular filtration rate (eGFR), and doubling of serum creatinine (SCr) </p> </li> <li> <p>Adverse events (including hyperkalaemia, acute kidney injury, and gynaecomastia).</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007004-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007004-sec-0015"></div> <section id="CD007004-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007004-sec-0017"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs of aldosterone antagonists used in combination with ACEi or ARB (or both) were included. Data from the first period of randomised cross‐over studies was also included. </p> </section> <section id="CD007004-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD007004-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>Studies enrolling participants with CKD stages 1 to 4, as defined by the by Kidney Disease Outcomes Quality Initiative (K‐DOQI) guidelines (<a href="./references#CD007004-bbs2-0100" title="LeveyAS ,  CoreshJ ,  BalkE ,  KauszAT ,  LevinA ,  SteffesMW ,  et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.[Erratum in: Ann Intern Med. 2003 Oct 7;139(7):605]. Annals of Internal Medicine2003;139(2):137-47. [MEDLINE: 12859163]">Levey 2003</a>) and who had albuminuria or proteinuria were considered for inclusion. We included studies in adults who had CKD regardless of aetiology. The K/DOQI categories for kidney disease are as follows.       </p> <p> <ul id="CD007004-list-0002"> <li> <p>CKD stage 1: eGFR &gt; 90 mL/min/1.73 m² and evidence of clinically relevant structural or urinary abnormalities including haematuria or proteinuria (or both) </p> </li> <li> <p>CKD stage 2: eGFR 60 to 89 mL/min/1.73 m²</p> </li> <li> <p>CKD stage 3: eGFR 30 to 59 mL/1.73 m²</p> </li> <li> <p>CKD stage 4: eGFR 15 to 29 mL/min/1.73 m².</p> </li> </ul> </p> </section> <section id="CD007004-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>We excluded studies in adults on dialysis, recipients of a kidney transplant, participants without evidence of CKD or proteinuria, studies less than 4 weeks of duration, and studies not evaluating any outcome of interest. </p> </section> </section> <section id="CD007004-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included studies evaluating aldosterone antagonist treatment given in combination with an ACEi or ARB (or both). We considered studies in which treatment duration was 4 weeks or longer. If any studies compared aldosterone antagonists alone (i.e. no additional RAS antagonists), these studies were also included, </p> <p>We considered the following treatment comparisons.</p> <p> <ul id="CD007004-list-0003"> <li> <p>Aldosterone antagonists with RAS antagonists versus placebo or standard care</p> </li> <li> <p>Aldosterone antagonist with RAS antagonists versus diuretic plus ACEi or ARB</p> </li> <li> <p>Non‐selective aldosterone antagonist with RAS antagonists versus calcium channel blocker</p> </li> <li> <p>Selective aldosterone antagonist with RAS antagonists versus ACEi or ARB (or both)</p> </li> <li> <p>Selective aldosterone antagonist with RAS antagonists versus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate </p> </li> <li> <p>Selective aldosterone antagonist with RAS antagonists versus non‐steroidal mineralocorticoid antagonist. </p> </li> </ul> </p> <p>If disaggregated outcome data were not available for the three groups (ACEi alone, ARB alone or the combination separately), we used combined data when available. </p> </section> <section id="CD007004-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD007004-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007004-list-0004"> <li> <p>Kidney failure (defined as permanent worsening in eGFR requiring kidney replacement therapy) </p> </li> <li> <p>Hyperkalaemia (defined as serum potassium &gt; 5.0 mEq/L or mmol/L)</p> </li> </ul> </p> </section> <section id="CD007004-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007004-list-0005"> <li> <p>Death (any cause)</p> </li> <li> <p>Major cardiovascular events as defined by the investigators (including but not limited to myocardial infarction, stroke, congestive heart failure) </p> </li> <li> <p>Urinary protein excretion rate (24‐hour proteinuria, 24‐hour albuminuria in mg/dL, urine protein:creatinine ratio, or urine albumin:creatinine ratio) </p> </li> <li> <p>Kidney function: estimated GFR (mL/min or mL/min/1.73 m²); doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria </p> </li> <li> <p>Blood pressure: systolic and diastolic blood pressure (mmHg)</p> </li> <li> <p>Serum potassium</p> </li> <li> <p>Acute kidney injury</p> </li> <li> <p>Gynaecomastia</p> </li> <li> <p>Fatigue</p> </li> <li> <p>Falls</p> </li> </ul> </p> </section> </section> </section> <section id="CD007004-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007004-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 13 January 2020 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD007004-list-0006"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals, and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD007004-sec-0133">Appendix 1</a> for search terms used in strategies for this review update. </p> </section> <section id="CD007004-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD007004-list-0007"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD007004-sec-0028"> <h3 class="title" id="CD007004-sec-0028">Data collection and analysis</h3> <p>Disagreements were resolved in consultation with two authors who also provided methodological assistance throughout the review process. </p> <section id="CD007004-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies relevant to the review. For this update, titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews that may have included relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary, the full text, of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD007004-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data were used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancies between published versions were highlighted. </p> </section> <section id="CD007004-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD007004-bbs2-0092" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD007004-sec-0134">Appendix 2</a>). </p> <p> <ul id="CD007004-list-0008"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD007004-list-0009"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Were reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>Discrepancies were resolved by discussion with a third author.</p> </section> <section id="CD007004-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (kidney failure, death (any cause), cardiovascular events, doubling of SCr, hyperkalaemia, acute kidney injury, and gynaecomastia) results were expressed as a risk ratio (RR) with 95% confidence intervals (CI). When continuous scales of measurement were used to assess the effects of treatment (end of treatment protein excretion rate or albumin excretion rate, eGFR or creatinine clearance, blood pressure, and serum potassium), we used the mean difference (MD) or the standardised mean difference (SMD) when different measurement scales were used. </p> </section> <section id="CD007004-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to seek additional information. We were successful in obtaining additional data from Drs KJ Schjoedt, K Rossing, A Chrysostomou, S Bianchi, S Nielsen, and K Takebayashi. These data were included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat (ITT), as‐treated and per‐protocol (PP) population were performed. Attrition rates, such as drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods were critically appraised (<a href="./references#CD007004-bbs2-0092" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD007004-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD007004-bbs2-0091" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values was as follows. </p> <p> <ul id="CD007004-list-0010"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or a confidence interval for I²) (<a href="./references#CD007004-bbs2-0092" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD007004-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess for the potential existence of small study bias (<a href="./references#CD007004-bbs2-0092" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) for outcomes in which sufficient data observations were available (10 or more studies) and in which there was low or no statistical heterogeneity between studies. </p> </section> <section id="CD007004-sec-0036"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using random effects meta‐analysis, but the fixed effects model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD007004-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity. Heterogeneity among participants could be related to age, stage of kidney disease, aetiology of kidney disease and amount of proteinuria. Heterogeneity in treatments could be related to prior agent(s) used and the agent (selective or non‐selective aldosterone antagonist), dose, duration of aldosterone antagonists and the concomitant use of ACEi or ARB (or both). </p> </section> <section id="CD007004-sec-0038"> <h4 class="title">'Summary of findings' tables</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD007004-bbs2-0115" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD007004-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD007004-bbs2-0089" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD007004-bbs2-0116" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. The absolute treatment effects for dichotomous outcomes was estimated using the risk estimate and 95% CI obtained from the corresponding meta‐analysis. </p> <section id="CD007004-sec-0039"> <h5 class="title">Primary efficacy outcome</h5> <p> <ul id="CD007004-list-0011"> <li> <p>Kidney failure</p> </li> </ul> </p> </section> <section id="CD007004-sec-0040"> <h5 class="title">Primary safety outcome</h5> <p> <ul id="CD007004-list-0012"> <li> <p>Hyperkalaemia</p> </li> </ul> </p> </section> <section id="CD007004-sec-0041"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007004-list-0013"> <li> <p>Death (any cause)</p> </li> <li> <p>Cardiovascular events</p> </li> <li> <p>Doubling SCr</p> </li> <li> <p>Acute kidney injury</p> </li> <li> <p>Proteinuria</p> </li> <li> <p>eGFR</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007004-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007004-sec-0042"></div> <section id="CD007004-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD007004-sec-0044"> <h4 class="title">Results of the search</h4> <p>For this 2020 update a search of The Cochrane Kidney and Transplant Register of Studies identified 83 reports. We identified 18 new included studies (32 reports), and four reports of two existing included studies; three new ongoing studies (four reports); 13 new excluded studies (40 reports), and two reports of two existing excluded studies. One study (one report) has been recently completed but no results have been published and is awaiting assessment. </p> <p>In addition to the new reports, one previously included study has been move to excluded (<a href="./references#CD007004-bbs2-0061" title="SchjoedtKJ , RossingK , JuhlTR , BoomsaF , TarnowL , RossingP , et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International2006;70(3):536-42. [MEDLINE: 16775595]">Schjoedt 2006</a>) as a proportion of the patients have been reported in two other included studies (<a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>). Two previous ongoing studies have now been included (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>) and one study, while complete, is yet to publish any results and is awaiting assessment (<a href="./references#CD007004-bbs2-0072" title="DeinumJ . Eplerenone, ACE inhibition and albuminuria. www.clinicaltrials.gov/ct2/show/NCT00315016 (first received 17 April 2006). ">NCT00315016</a>). Four non‐RCTs have been removed from this update. </p> <p>See <a href="#CD007004-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007004-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007004-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007004-sec-0045"> <h4 class="title">Included studies</h4> <p>For this 2020 update we included 18 new studies (4248 participants) (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>; <a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0020" title="HamidN , TaherM . Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors [abstract no: P113]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):11-2. [EMBASE: 616611416]NoshadH , ManzariT . Hydrochlorothiazide or spironolacton in diabetic nephropathy [abstract no: SP446]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii273. [EMBASE: 617291179]">Hamid 2017a</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>; <a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>; <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a>; <a href="./references#CD007004-bbs2-0044" title="ZiaeeA , Abbas VaeziA , OveisiS , JavadiA , HashemipourS , KazemifarAM . Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian Journal of Internal Medicine2013;4(2):648-53. [EMBASE: 369112192]">Ziaee 2013</a>). This brings the total number of included studies to 44 (85 reports, 5745 participants). </p> <p>Ten studies were cross‐over studies (<a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>). </p> <p>Twenty‐three studies included participants who had kidney disease secondary to diabetes mellitus (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0020" title="HamidN , TaherM . Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors [abstract no: P113]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):11-2. [EMBASE: 616611416]NoshadH , ManzariT . Hydrochlorothiazide or spironolacton in diabetic nephropathy [abstract no: SP446]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii273. [EMBASE: 617291179]">Hamid 2017a</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>; <a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0026" title="KoroshiA , IdriziA , GjergjiZ , HoxhaB , EmrullajE , SpahiaE , et al. Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]. NDT Plus2010;3(Suppl 3):iii424. [EMBASE: 70484562]">Koroshi 2010</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0032" title="OgawaS , TakeuchiK , MoriT , NakoK , ItoS . Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clinical &amp; Experimental Pharmacology &amp; Physiology2006;33(5-6):477-9. [MEDLINE: 16700881]">Ogawa 2006a</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>; <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a>; <a href="./references#CD007004-bbs2-0044" title="ZiaeeA , Abbas VaeziA , OveisiS , JavadiA , HashemipourS , KazemifarAM . Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian Journal of Internal Medicine2013;4(2):648-53. [EMBASE: 369112192]">Ziaee 2013</a>). Two studies included participants with heart failure with associated proteinuric CKD (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>). The remaining studies included participants with non‐diabetic kidney disease encompassing IgA nephropathy, benign nephrosclerosis, membranous nephropathy, or idiopathic chronic glomerulonephritis (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>; <a href="./references#CD007004-bbs2-0027" title="LvJ , QinS , LiY , ZhangH , LiuL , ShiS , et al. Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus2009;2(Suppl 2):ii1029. [CENTRAL: CN-01657692] ">Lv 2009a</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>; <a href="./references#CD007004-bbs2-0038" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):525A. [CENTRAL: CN-01657689] ">Tokunaga 2008a</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>; <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a>). All studies excluded participants with an eGFR below 15 mL/min/1.73 m². For studies measuring 24‐hour urine protein or albumin, the baseline albuminuria/proteinuria excretion rates ranged from 0.15 to 3.6 g/day. Study duration varied from one to 36 months with a median duration of 3 months. Sample size of all studies was variable (range 16 to 1055) and none were powered to detect hard primary outcomes including kidney failure, death, or major cardiovascular events. </p> <p>Among studies using non‐selective aldosterone antagonists, 22 studies (1441 participants) compared spironolactone plus ACEi or ARB (or both) to ACEi or ARB (or both) (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0026" title="KoroshiA , IdriziA , GjergjiZ , HoxhaB , EmrullajE , SpahiaE , et al. Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]. NDT Plus2010;3(Suppl 3):iii424. [EMBASE: 70484562]">Koroshi 2010</a>; <a href="./references#CD007004-bbs2-0027" title="LvJ , QinS , LiY , ZhangH , LiuL , ShiS , et al. Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus2009;2(Suppl 2):ii1029. [CENTRAL: CN-01657692] ">Lv 2009a</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0032" title="OgawaS , TakeuchiK , MoriT , NakoK , ItoS . Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clinical &amp; Experimental Pharmacology &amp; Physiology2006;33(5-6):477-9. [MEDLINE: 16700881]">Ogawa 2006a</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0038" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):525A. [CENTRAL: CN-01657689] ">Tokunaga 2008a</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>; <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a>; <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a>; <a href="./references#CD007004-bbs2-0044" title="ZiaeeA , Abbas VaeziA , OveisiS , JavadiA , HashemipourS , KazemifarAM . Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian Journal of Internal Medicine2013;4(2):648-53. [EMBASE: 369112192]">Ziaee 2013</a>). Five studies (220 participants) compared spironolactone plus ACEi or ARB to diuretics plus ACEi or ARB (<a href="./references#CD007004-bbs2-0020" title="HamidN , TaherM . Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors [abstract no: P113]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):11-2. [EMBASE: 616611416]NoshadH , ManzariT . Hydrochlorothiazide or spironolacton in diabetic nephropathy [abstract no: SP446]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii273. [EMBASE: 617291179]">Hamid 2017a</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>, <a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>); one study (37 participants) compared spironolactone to calcium channel blockers (<a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a>); one study (136 participants) compared spironolactone plus ARB to ACEi plus ARB (<a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>); one study (120 participants) compared canrenone plus ARB and calcium channel blockers to hydrochlorothiazide plus ARB and calcium channel blockers (<a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>); and one study (128 participants) compared spironolactone plus ACEi and ARB to ACEi (<a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>). In the studies that analysed the efficacy of non‐selective aldosterone antagonists, 25 mg/day of spironolactone was used throughout the study period except for <a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>, <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a> and <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a> who used 25 to 50 mg/day. <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>, <a href="./references#CD007004-bbs2-0027" title="LvJ , QinS , LiY , ZhangH , LiuL , ShiS , et al. Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus2009;2(Suppl 2):ii1029. [CENTRAL: CN-01657692] ">Lv 2009a</a>, <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a> and <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a> used 20 mg/day; <a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>, <a href="./references#CD007004-bbs2-0026" title="KoroshiA , IdriziA , GjergjiZ , HoxhaB , EmrullajE , SpahiaE , et al. Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]. NDT Plus2010;3(Suppl 3):iii424. [EMBASE: 70484562]">Koroshi 2010</a>and <a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a> used 50 mg/day; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a> used 12.5 to 25 mg/day of spironolactone; and <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> used 25 mg three times/week to 50 mg/day of spironolactone. <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a> used 25 mg/day of canrenone. In <a href="./references#CD007004-bbs2-0020" title="HamidN , TaherM . Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors [abstract no: P113]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):11-2. [EMBASE: 616611416]NoshadH , ManzariT . Hydrochlorothiazide or spironolacton in diabetic nephropathy [abstract no: SP446]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii273. [EMBASE: 617291179]">Hamid 2017a</a>, the dose of spironolactone was not defined. </p> <p>Six studies (925 participants) compared the selective aldosterone antagonist eplerenone plus ACEi or ARB (or both) to ACEi or ARB (or both) (<a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>). One study (34 participants) compared eplerenone plus ACEi or ARB (or both) to ACEi or ARB (or both) and to ACEi or ARB (or both) plus nitrate (<a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>), and one study (54 participants) compared the selective aldosterone antagonist eplerenone to placebo (<a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>). Studies that analysed the efficacy of selective aldosterone antagonists used eplerenone at the dose of 200 mg/day (<a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>), 50 to 100 mg/day (<a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>), 25 to 50 mg/day (<a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>), and 50 mg/day (<a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>). In <a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a> the dose of eplerenone administered was not defined. </p> <p>One cross‐over study (12 participants) compared eplerenone alone (25 mg/day) to ACEi alone (20 mg/day) or ACEi (10 mg/day) plus ARB (16 mg/day) (<a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>). </p> <p>Among studies using non‐steroidal mineralocorticoid antagonists, one study (821 participants) compared finerenone to placebo (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>), one study (392 participants) compared finerenone to placebo or spironolactone (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>), one study (1055 participants) compared finerenone to eplerenone (<a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>), and one study (358 participants) compared esaxerenone to placebo (<a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>). Studies that analysed the efficacy of non‐steroidal mineralocorticoid antagonists used finerenone at the dose of 2.5 to 10 mg/day (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>), 1.25 to 25 mg/day (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>), 5 to 20 mg/day (<a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>), and esaxerenone 0.625 to 5 mg/day (<a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>). Other characteristics of the participants and the interventions of the included studies are detailed in the <a href="./references#CD007004-sec-0140" title="">Characteristics of included studies</a>. </p> </section> <section id="CD007004-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Twenty‐seven studies (61 reports) were excluded because; they did not include adults with CKD (17 studies); were not studies comparing aldosterone antagonists with or without ACEi or ARB (3); were of short duration (1); included participants already reported in other included studies (1); were terminated early with no reported outcomes (1); or they did not examine outcomes of interest (e.g. pharmacokinetic studies) (1). One study was retracted (1). </p> <p>For this 2020 update, non‐RCTs have been deleted.</p> <p>See <a href="./references#CD007004-sec-0141" title="">Characteristics of excluded studies</a> </p> </section> </section> <section id="CD007004-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Risks of bias in the available studies are shown in <a href="#CD007004-fig-0003">Figure 3</a> and <a href="#CD007004-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD007004-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007004-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007004-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007004-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007004-sec-0048"> <h4 class="title">Allocation</h4> <p>Random sequence generation was judged to be at low risk of bias in 12 studies (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>) and unclear in the remaining 32 studies. </p> <p>Allocation concealment was judged to be at low risk in five studies (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>), one study was judged to be a high risk of bias (<a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>), and unclear in the remaining 38 studies. </p> </section> <section id="CD007004-sec-0049"> <h4 class="title">Blinding</h4> <p>Participants and investigators were blinded in 18 studies (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>; <a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0027" title="LvJ , QinS , LiY , ZhangH , LiuL , ShiS , et al. Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus2009;2(Suppl 2):ii1029. [CENTRAL: CN-01657692] ">Lv 2009a</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>) and not blinded in 13 studies (<a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0038" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):525A. [CENTRAL: CN-01657689] ">Tokunaga 2008a</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a>); blinding was unclear in the remaining 13 studies. </p> <p>Outcome assessors were not aware of treatment allocation or outcomes were unlikely influenced by treatment allocation in 15 studies (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>; <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a>). Blinding of outcome assessors was unclear in the remaining 29 studies. </p> </section> <section id="CD007004-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐four studies were judged to be at low risk of bias (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>; <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a>). Seven studies where there was some loss to follow‐up (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>) were analysed on an intention‐to‐treat basis. Ten studies were judged to be at high risk of bias (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>). The dropout rate from study follow‐up ranged from 0% to 37% and did not differ between the treatment and control groups. </p> </section> <section id="CD007004-sec-0051"> <h4 class="title">Selective reporting</h4> <p>All the pre‐specified outcomes and all relevant outcomes were reported in 18 studies (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0009" title="ChenY , LiuP , ChenX , LiY , ZhangF , WangY . Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. American Journal of the Medical Sciences2018;355(5):418-24. [MEDLINE: 29753370]">Chen 2018b</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0015" title="EsteghamatiA , NoshadS , JarrahS , MousavizadehM , KhoeeSH , NakhjavaniM . Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation2013;28(11):2823-33. [MEDLINE: 24009294]">Esteghamati 2013</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>; <a href="./references#CD007004-bbs2-0027" title="LvJ , QinS , LiY , ZhangH , LiuL , ShiS , et al. Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]. NDT Plus2009;2(Suppl 2):ii1029. [CENTRAL: CN-01657692] ">Lv 2009a</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0038" title="TokunagaM , TamuraM , KabashimaN , SerinoR , ShibataT , MatsumotoM , et al. Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):525A. [CENTRAL: CN-01657689] ">Tokunaga 2008a</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>). Selective reporting was judged to be at high risk of bias in 23 studies (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>; <a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0020" title="HamidN , TaherM . Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors [abstract no: P113]. Iranian Journal of Kidney Diseases2017;11(Suppl 1):11-2. [EMBASE: 616611416]NoshadH , ManzariT . Hydrochlorothiazide or spironolacton in diabetic nephropathy [abstract no: SP446]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii273. [EMBASE: 617291179]">Hamid 2017a</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>; <a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>; <a href="./references#CD007004-bbs2-0026" title="KoroshiA , IdriziA , GjergjiZ , HoxhaB , EmrullajE , SpahiaE , et al. Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]. NDT Plus2010;3(Suppl 3):iii424. [EMBASE: 70484562]">Koroshi 2010</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0032" title="OgawaS , TakeuchiK , MoriT , NakoK , ItoS . Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clinical &amp; Experimental Pharmacology &amp; Physiology2006;33(5-6):477-9. [MEDLINE: 16700881]">Ogawa 2006a</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>; <a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>; <a href="./references#CD007004-bbs2-0042" title="WangW , LiL , ZhouZ , GaoJ , SunY . Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Experimental &amp; Therapeutic Medicine2013;6(6):1527-31. [MEDLINE: 24255685]">Wang 2013g</a>; <a href="./references#CD007004-bbs2-0043" title="ZhengH , QiuH , LiuX , JiangB . Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharmaceutical Care &amp; Research2011;11(4):266-8. [EMBASE: 2011509942]">Zheng 2011</a>; <a href="./references#CD007004-bbs2-0044" title="ZiaeeA , Abbas VaeziA , OveisiS , JavadiA , HashemipourS , KazemifarAM . Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian Journal of Internal Medicine2013;4(2):648-53. [EMBASE: 369112192]">Ziaee 2013</a>), and unclear in the remaining three studies. </p> </section> <section id="CD007004-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Eighteen studies were judged to be at low risk of bias due to funding (<a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>; <a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a>; <a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0021" title="HaseM , BabazonoT , UjiharaN , UchigataY . Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. Journal of Diabetes Investigation2013;4(3):316-9. [MEDLINE: 24843672]">Hase 2013</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>; <a href="./references#CD007004-bbs2-0041" title="vanden MeirackerAH , BaggenRG , PauliS , LindemansA , VultoAG , PoldermansD . Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. Journal of Hypertension2006;24(11):2285-92. [MEDLINE: 17053552]">van den Meiracker 2006</a>; <a href="./references#CD007004-bbs2-0044" title="ZiaeeA , Abbas VaeziA , OveisiS , JavadiA , HashemipourS , KazemifarAM . Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: a pilot randomized clinical trial. Caspian Journal of Internal Medicine2013;4(2):648-53. [EMBASE: 369112192]">Ziaee 2013</a>); six studies were funded by a pharmaceutical company (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>; <a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0016" title="AndoK , OhtsuH , ArakawaY , KubotaK , YamaguchiT , NagaseM , et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research - Clinical &amp; Experimental2010;33(6):616-21. [MEDLINE: 20379190]AndoK , OhtsuH , UchidaS , KanameS , ArakawaY , FujitaT , et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes &amp; Endocrinology2014;2(12):944-53. [MEDLINE: 25466242]FujitaT , UchidaS , SekiG , KanameS . The antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria: a double-blinded, randomized, placebo-controlled (EVALUATE) trial [abstract no: SA-PO1081]. Journal of the American Society of Nephrology2013;24(Abstract Suppl):3B. ">EVALUATE 2010</a>; <a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>;); one study excluded participants after randomisation due change in treatment (<a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>) and the risk of bias was unclear in the remaining 19 studies. </p> </section> </section> <section id="CD007004-sec-0053"> <h3 class="title" id="CD007004-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD007004-tbl-0001"><b>Summary of findings 1</b> Aldosterone antagonists versus placebo or standard care for proteinuric chronic kidney disease</a>; <a href="./full#CD007004-tbl-0002"><b>Summary of findings 2</b> Aldosterone antagonists versus diuretics for proteinuric chronic kidney disease</a>; <a href="./full#CD007004-tbl-0003"><b>Summary of findings 3</b> Aldosterone antagonists versus calcium channel blockers for proteinuric chronic kidney disease</a>; <a href="./full#CD007004-tbl-0004"><b>Summary of findings 4</b> Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</a>; <a href="./full#CD007004-tbl-0005"><b>Summary of findings 5</b> Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</a>; <a href="./full#CD007004-tbl-0006"><b>Summary of findings 6</b> Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</a> </p> <section id="CD007004-sec-0054"> <h4 class="title">Aldosterone antagonists (selective or non‐selective) versus placebo or standard care</h4> <section id="CD007004-sec-0055"> <h5 class="title">Kidney failure</h5> <p>In very low certainty evidence, aldosterone antagonists have uncertain effects on kidney failure (<a href="./references#CD007004-fig-0011" title="">Analysis 1.1</a> (2 studies, 84 participants): RR 3.00, 95% CI 0.33 to 27.65; I² = 0%) (<a href="#CD007004-fig-0005">Figure 5</a>) compared to placebo or standard care. </p> <div class="figure" id="CD007004-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Effect of aldosterone antagonists versus placebo or standard care on kidney failure" data-id="CD007004-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on kidney failure</p> </div> </div> </div> </section> <section id="CD007004-sec-0056"> <h5 class="title">Hyperkalaemia</h5> <p>In moderate certainty evidence, aldosterone antagonists probably increases risk of hyperkalaemia (<a href="./references#CD007004-fig-0012" title="">Analysis 1.2</a> (17 studies, 3001 participants): RR 2.17, 95% CI 1.47 to 3.22; I² = 0%) (numbers needed to treat for an additional harmful outcome (NNTH) 41) (<a href="#CD007004-fig-0006">Figure 6</a>) compared to placebo or standard care, regardless of whether aldosterone antagonists were combined with one ACEi or ARB (<a href="./references#CD007004-fig-0013" title="">Analysis 1.3</a>.1 (11 studies, 1828 participants): RR 2.05, 95% CI 1.28 to 3.28; I² = 0%), or combined with ACEi plus ARB (<a href="./references#CD007004-fig-0013" title="">Analysis 1.3</a>.2 (4 studies, 149 participants): RR 4.30, 95% CI 1.12 to 16.51; I² = 0%). </p> <div class="figure" id="CD007004-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Effect of aldosterone antagonists versus placebo or standard care on hyperkalaemia" data-id="CD007004-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on hyperkalaemia</p> </div> </div> </div> </section> <section id="CD007004-sec-0057"> <h5 class="title">Death</h5> <p>In low certainty evidence, aldosterone antagonists have uncertain effects on death (any cause) (<a href="./references#CD007004-fig-0015" title="">Analysis 1.5</a> (3 studies, 421 participants): RR 0.58, 95% CI 0.10 to 3.50; I² = 0%) compared to placebo or standard care. </p> </section> <section id="CD007004-sec-0058"> <h5 class="title">Cardiovascular events</h5> <p>In low certainty evidence, aldosterone antagonists have uncertain effects on cardiovascular events (<a href="./references#CD007004-fig-0016" title="">Analysis 1.6</a> (3 studies, 1067 participants): RR 0.95, 95% CI 0.26 to 3.56; I² = 42%) compared to placebo or standard care. </p> <p><a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a> reported one myocardial infarction in the aldosterone antagonist group. Meta‐analysis was not performed. </p> <p>Aldosterone antagonists had uncertain effects on stroke compared to placebo or standard care (<a href="./references#CD007004-fig-0018" title="">Analysis 1.8</a> (3 studies, 1233 participants): RR 0.65, 95% CI 0.12 to 3.44; I² = 11%). </p> </section> <section id="CD007004-sec-0059"> <h5 class="title">Proteinuria</h5> <p>In very low certainty evidence, aldosterone antagonists may reduce proteinuria (<a href="./references#CD007004-fig-0019" title="">Analysis 1.9</a> (14 studies, 1193 participants): SMD ‐0.51, 95% CI ‐0.82 to ‐0.20; I² = 82%) (<a href="#CD007004-fig-0007">Figure 7</a>) compared to placebo or standard care. There was significant heterogeneity. </p> <div class="figure" id="CD007004-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Effect of aldosterone antagonists versus placebo or standard care on proteinuria." data-id="CD007004-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on proteinuria.</p> </div> </div> </div> </section> <section id="CD007004-sec-0060"> <h5 class="title">Kidney function</h5> <section id="CD007004-sec-0061"> <h6 class="title">Glomerular filtration rate</h6> <p>In low certainty evidence, aldosterone antagonists may reduce eGFR (<a href="./references#CD007004-fig-0022" title="">Analysis 1.12</a> (13 studies, 1165 participants): MD ‐3.00 mL/min/1.73 m², 95% CI ‐5.51 to ‐0.49; I² = 0%) (<a href="#CD007004-fig-0008">Figure 8</a>) compared to placebo or standard care. </p> <div class="figure" id="CD007004-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Effect of aldosterone antagonists versus placebo or standard care on GFR [mL/min/1.73 m²]." data-id="CD007004-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on GFR [mL/min/1.73 m²]. </p> </div> </div> </div> </section> <section id="CD007004-sec-0062"> <h6 class="title">Doubling of serum creatinine</h6> <p>Two studies (<a href="./references#CD007004-bbs2-0003" title="BakrisGL , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA2015;314(9):884-94. [MEDLINE: 26325557]KatayamaS , YamadaD , NakayamaM , YamadaT , MyoishiM , KatoM , et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Diabetes &amp; its Complications2017;31(4):758-65. [MEDLINE: 28025025]RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Effects of finerenone in patients with diabetic nephropathy [abstract]. In: ISN World Congress of Nephrology; 2015 March 13-17; Cape Town, South Africa. 2015. RuilopeLM , AgarwalR , ChanJC , CooperME , GansevoortRT , HallerH , et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. American Journal of Nephrology2015;40(6):572-81. [MEDLINE: 25591469]">ARTS‐DN 2015</a>; <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>) reported doubling of SCr (or equivalent eGFR decline ≥ 57%) with events only occurring in <a href="./references#CD007004-bbs2-0028" title="MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology2009;20(12):2641-50. [MEDLINE: 19926893]MehdiUF , Adams-HuetB , RaskinP , VegaGL , TotoRD . Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):28A. [CENTRAL: CN-00756304] SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on lipoprotein metabolism in diabetic nephropathy [abstract no: 266]. American Journal of Kidney Diseases2012;59(4):A81. [EMBASE: 71074879]SrivastavaA , Adams-HuetB , VegaGL , TotoRD . Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. Journal of Investigative Medicine2016;64(6):1102-8. [MEDLINE: 27388615]Van BurenPN , Adams-HuetB , NguyenM , MolinaC , TotoRD . Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clinical Journal of the American Society of Nephrology: CJASN2014;9(2):295-301. [MEDLINE: 24408116]Van BurenPN , Adams-HuetB , TotoRD . Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. Journal of Investigative Medicine2010;58(8):950-6. [MEDLINE: 21030879]">Mehdi 2009</a>. Meta‐analysis was not performed. </p> </section> </section> <section id="CD007004-sec-0063"> <h5 class="title">Blood pressure</h5> <p>In very low certainty evidence, aldosterone antagonists may reduce systolic blood pressure (<a href="./references#CD007004-fig-0026" title="">Analysis 1.16</a> (14 studies, 911 participants): MD ‐4.98 mmHg, 95% CI ‐8.22 to ‐1.75; I² = 87%) but had uncertain effects on diastolic blood pressure (<a href="./references#CD007004-fig-0027" title="">Analysis 1.17</a> (13 studies, 875 participants): MD ‐1.04 mmHg, 95% CI ‐2.82 to 0.73; I² = 79%) compared to placebo or standard care. There was significant heterogeneity in both analyses. </p> </section> <section id="CD007004-sec-0064"> <h5 class="title">Serum potassium</h5> <p>In very low certainty evidence, aldosterone antagonists may increase serum potassium (<a href="./references#CD007004-fig-0030" title="">Analysis 1.20</a> (17 studies, 1326 participants): MD 0.19 mEq/L, 95% CI 0.10 to 0.29; I² = 81%) compared to placebo or standard care. There was significant heterogeneity. </p> </section> <section id="CD007004-sec-0065"> <h5 class="title">Acute kidney injury</h5> <p>In moderate certainty evidence, aldosterone antagonists probably increases the risk of acute kidney injury (<a href="./references#CD007004-fig-0032" title="">Analysis 1.22</a> (5 studies, 1446 participants): RR 1.94, 95% CI 0.99 to 3.79; I² = 0%) compared to placebo or standard care. </p> </section> <section id="CD007004-sec-0066"> <h5 class="title">Gynaecomastia</h5> <p>In moderate certainty evidence, aldosterone antagonists probably increases the risk of gynaecomastia (<a href="./references#CD007004-fig-0033" title="">Analysis 1.23</a> (4 studies, 281 participants): RR 5.14, 95% CI 1.14 to 23.23; I² = 0%) compared to placebo or standard care. </p> </section> <section id="CD007004-sec-0067"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria; regression from micro‐ to normoalbuminuria; falls; and fatigue. </p> </section> <section id="CD007004-sec-0068"> <h5 class="title">Analysis of heterogeneity</h5> <p>Heterogeneity in the effects of spironolactone on proteinuria was explored through sub‐group analyses. </p> <section id="CD007004-sec-0069"> <h6 class="title">Baseline kidney disease</h6> <p>Aldosterone antagonists reduced proteinuria in diabetic kidney disease (<a href="./references#CD007004-fig-0019" title="">Analysis 1.9</a>.1 (7 studies, 572 participants): SMD ‐0.46, 95% CI ‐0.64 to ‐0.27; I² = 0%) but had unclear effects on non‐diabetic kidney disease (<a href="./references#CD007004-fig-0019" title="">Analysis 1.9</a>.2 (5 studies, 367 participants): SMD ‐0.68, 95% CI ‐1.57 to 0.21; I² = 93%) compared to placebo or standard care. </p> <p>Aldosterone antagonists reduced systolic blood pressure to a greater extent in non‐diabetic kidney disease (<a href="./references#CD007004-fig-0026" title="">Analysis 1.16</a>.2 (5 studies, 367 participants): MD ‐3.35, 95% CI ‐5.06 to ‐1.65; I² = 0%) than diabetic kidney disease (<a href="./references#CD007004-fig-0026" title="">Analysis 1.16</a>.1 (5 studies, 228 participants): MD ‐1.07, 95% CI ‐1.82 to ‐0.32; I² = 0%) compared to placebo or standard care. </p> <p>Aldosterone antagonists reduced diastolic blood pressure in non‐diabetic kidney disease (<a href="./references#CD007004-fig-0027" title="">Analysis 1.17</a>.2 (4 studies, 331 participants): MD ‐1.62, 95% CI ‐2.86 to ‐0.38; I² = 0%) but had unclear effects on diabetic kidney disease (<a href="./references#CD007004-fig-0027" title="">Analysis 1.17</a>.1 (5 studies, 249 participants): MD ‐1.06, 95% CI ‐1.80 to ‐0.31; I² = 25%) compared to placebo or standard care. </p> <p>Aldosterone antagonists increased serum potassium in both diabetic kidney disease (<a href="./references#CD007004-fig-0030" title="">Analysis 1.20</a>.1 (9 studies, 664 participants): MD 0.21 mEq/L, 95% CI 0.14 to 0.28; I² = 0%) and non‐diabetic kidney disease (<a href="./references#CD007004-fig-0030" title="">Analysis 1.20</a>.2 (6 studies, 367 participants): MD 0.30 mEq/L, 95% CI 0.10 to 0.50; I² = 92%) compared to placebo or standard care. </p> </section> <section id="CD007004-sec-0070"> <h6 class="title">Study duration</h6> <p>Aldosterone antagonists reduced proteinuria in studies reporting follow‐up of less than six months (<a href="./references#CD007004-fig-0034" title="">Analysis 1.24</a>.1 (9 studies, 822 participants): SMD ‐0.39, 95% CI ‐0.54 to ‐0.24; I² = 0%) but had unclear effects in studies reporting follow‐up of longer than six months (<a href="./references#CD007004-fig-0034" title="">Analysis 1.24</a>.2 (4 studies, 331 participants): SMD ‐0.59, 95% CI ‐1.68 to 0.50; I² = 95%) compared to placebo or standard care. </p> <p>Aldosterone antagonists reduced systolic blood pressure in both studies reporting follow‐up of less than six months (<a href="./references#CD007004-fig-0035" title="">Analysis 1.25</a>.1 (10 studies, 580 participants): MD ‐5.65, 95% CI ‐10.96 to ‐0.33; I² = 90%) and studies reporting follow‐up of longer than six months (<a href="./references#CD007004-fig-0035" title="">Analysis 1.25</a>.2 (4 studies, 331 participants): MD ‐3.62, 95% CI ‐6.09 to ‐1.15; I² = 15%). </p> <p>Aldosterone antagonists reduced diastolic blood pressure in studies reporting follow‐up longer than six months (<a href="./references#CD007004-fig-0036" title="">Analysis 1.26</a>.2 (4 studies, 331 participants): MD ‐1.62, 95% CI ‐2.86 to ‐0.38; I² = 0%) but had unclear effect in studies reporting follow‐up less than six months (<a href="./references#CD007004-fig-0036" title="">Analysis 1.26</a>.1 (9 studies, 553 participants): MD ‐0.98, 95% CI ‐3.71 to 1.75; I² = 83%). </p> <p>Aldosterone antagonists increased serum potassium in both studies reporting follow up less than six months (<a href="./references#CD007004-fig-0037" title="">Analysis 1.27</a>.1 (12 studies, 954 participants): MD 0.16 mEq/L, 95% CI 0.10 to 0.22; I² = 23%) and studies reporting follow‐up longer than six months (<a href="./references#CD007004-fig-0037" title="">Analysis 1.27</a>.2 (4 studies, 331 participants): MD 0.35 mEq/L, 95% CI 0.04 to 0.65; I² = 93%). </p> </section> <section id="CD007004-sec-0071"> <h6 class="title">Aldosterone antagonist selectivity</h6> <p>A single study (<a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>) reported the effect of the selective aldosterone antagonist eplerenone on proteinuria, systolic blood pressure, diastolic blood pressure and serum potassium. All other studies reported the effect of the non‐selective aldosterone antagonist spironolactone on these outcomes. Subgroup analysis was not performed. </p> </section> <section id="CD007004-sec-0072"> <h6 class="title">Baseline proteinuria or albuminuria</h6> <p>Single studies specified baseline albuminuria &gt; 100mg/g (<a href="./references#CD007004-bbs2-0025" title="KatoS , MaruyamaS , MakinoH , WadaJ , OgawaD , UzuT , et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical &amp; Experimental Nephrology2015;19(6):1098-106. [MEDLINE: 25795029]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Renoprotective effects of combining RAS blockade drugs with spironolactone in patients with diabetic mephropathy and overt albuminuria [abstract no: MP302]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii428. [EMBASE: 71492704]KatoS , MaruyamaS , MakinoH , WadaJ , UzuT , ArakiH , et al. Spironolactone improving intrarenal renin-angiotensin system activation in type II diabetic nephropathy patients with overt albuminuria [abstract no: PS3-039]. Nephrology2014;19(Suppl 2):172. ">Kato 2015</a>), &gt; 300mg/g (<a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>), &gt; 300mg/day (<a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>) and 45 to 300 mg/day (<a href="./references#CD007004-bbs2-0024" title="ItoS , ShikataK , NangakuM , OkudaY , SawanoboriT . Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clinical Journal of the American Society of Nephrology: CJASN2019;14(8):1161-72. [MEDLINE: 31248950]">Ito 2019a</a>), and which reported on proteinuria and serum potassium. Subgroup analysis was not performed. </p> <p>Single studies specified baseline proteinuria &gt; 150mg/day (<a href="./references#CD007004-bbs2-0023" title="HorestaniMK , BehradmaneshS , MomeniA , BaradaranA . Effects of spironolactone on proteinuria of patients with type 2 diabetes. Journal of Isfahan Medical School2012;30(200). [EMBASE: 2012617320]MomeniA , BehradmaneshMS , KheiriS , Karami HorestaniM . Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System2015;16(1):113-8. [MEDLINE: 23486907]">Horestani 2012</a>), &gt; 0.3g/day (<a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>), &gt;1g/g (<a href="./references#CD007004-bbs2-0005" title="BianchiS , BigazziR , CampeseVM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International2006;70(12):2116-23. [MEDLINE: 17035949]BianchiS , BigazziR , CampeseVM . Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):33A. [CENTRAL: CN-00615828] ">Bianchi 2006</a>), and &gt; 1.5g/day (<a href="./references#CD007004-bbs2-0010" title="ChrysostomouA , PedagogosE , BrigantiE , BeckerGJ . A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]. Nephrology2005;10(Suppl 1):A137. [CENTRAL: CN-00602127] ChrysostomouA , PedagogosE , MacGregorL , BeckerGJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of the American Society of Nephrology: CJASN2006;1(2):256-62. [MEDLINE: 17699214]">Chrysostomou 2006</a>), and which reported on proteinuria, systolic blood pressure, diastolic blood pressure, and serum potassium. All other studies specified baseline proteinuria &gt; 0.5g/day or did not specific baseline proteinuria. Subgroup analysis was not performed. </p> </section> <section id="CD007004-sec-0073"> <h6 class="title">Baseline kidney function</h6> <p>Single studies specified baseline eGFR 15 to 60 mL/min/1.73 m² (<a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>), eGFR 25 to 50 mL/min/1.73 m² (<a href="./references#CD007004-bbs2-0001" title="AbolghasmiR , TazikiO . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi Journal of Kidney Diseases &amp; Transplantation2011;22(1):75-8. [MEDLINE: 21196617]">Abolghasmi 2011</a>), eGFR &gt; 45 mL/min/1.73 m² (<a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>), and which reported on proteinuria, systolic blood pressure, diastolic blood pressure, and serum potassium. All other studies specified baseline eGFR &gt; 30 mL/min/1.73 m² or did not specific baseline kidney function. Subgroup analysis was not performed. </p> </section> </section> </section> <section id="CD007004-sec-0074"> <h4 class="title">Non‐selective aldosterone antagonists (spironolactone or canrenone) plus ACEi or ARB versus diuretics plus ACEi or ARB </h4> <section id="CD007004-sec-0075"> <h5 class="title">Proteinuria</h5> <p>In very low certainty evidence, non‐selective aldosterone antagonists plus ACEi or ARB had an uncertain effect on proteinuria (<a href="./references#CD007004-fig-0038" title="">Analysis 2.1</a> (2 studies, 139 participants): SMD ‐1.59, 95% CI ‐3.80 to 0.62; I² = 93%) compared to diuretics plus ACEi or ARB. There was significant heterogeneity. </p> </section> <section id="CD007004-sec-0076"> <h5 class="title">Glomerular filtration rate</h5> <p>One study reported eGFR (<a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>) and one cross‐over study (<a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>) did not report individual study periods. Meta‐analysis was not performed due to inability to combine study data. </p> </section> <section id="CD007004-sec-0077"> <h5 class="title">Blood pressure</h5> <p>In very low certainty evidence, non‐selective aldosterone antagonists plus ACEi or ARB had an uncertain effect on systolic blood pressure (<a href="./references#CD007004-fig-0045" title="">Analysis 2.8</a> (3 studies, 151 participants): MD ‐3.79, 95% CI ‐14.36 to 6.79; I² = 90%) and diastolic blood pressure (<a href="./references#CD007004-fig-0044" title="">Analysis 2.7</a> (3 studies, 151 participants): MD ‐1.56, 95% CI ‐3.52 to 0.41; I² = 3%) compared to diuretics plus ACEi or ARB. There was significant heterogeneity in the analysis for systolic blood pressure. </p> </section> <section id="CD007004-sec-0078"> <h5 class="title">Serum potassium</h5> <p>In low certainty evidence, non‐selective aldosterone antagonists plus ACEi or ARB may increase serum potassium (<a href="./references#CD007004-fig-0048" title="">Analysis 2.11</a> (2 studies, 121 participants): MD 0.31, 95% CI 0.17 to 0.45; I² = 0%) compared to diuretics plus ACEi or ARB. </p> </section> <section id="CD007004-sec-0079"> <h5 class="title">Fatigue</h5> <p><a href="./references#CD007004-bbs2-0017" title="FogariR , DerosaG , ZoppiA , LazzariP , D'AngeloA , MugelliniA . Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opinion on Pharmacotherapy2014;15(4):453-9. [MEDLINE: 24410484]">Fogari 2014</a> reported no difference in fatigue between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0080"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; hyperkalaemia; death (any cause); cardiovascular events; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria; acute kidney injury; gynaecomastia; and falls. </p> </section> </section> <section id="CD007004-sec-0081"> <h4 class="title">Non‐selective aldosterone antagonists (spironolactone) versus calcium channel blockers</h4> <section id="CD007004-sec-0082"> <h5 class="title">Proteinuria</h5> <p><a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a> reported spironolactone reduced urinary albumin excretion but did not change in amlodipine group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0083"> <h5 class="title">Blood pressure</h5> <p><a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a>reported no change in systolic or diastolic blood pressure between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0084"> <h5 class="title">Serum potassium</h5> <p><a href="./references#CD007004-bbs2-0037" title="MatsumotoS , TakebayashiK , AsoY . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism: Clinical &amp; Experimental2006;55(12):1645-52. [MEDLINE: 17142138]TakebayashiK , MatsumotoS , AsoY , InukaiT . Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2214-7. [MEDLINE: 16569732]">Takebayashi 2006</a> reported serum potassium was lower in the calcium channel blocker group compared to the spironolactone group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0085"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; hyperkalaemia; death (any cause); cardiovascular events; eGFR; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria; blood pressure; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0086"> <h4 class="title">Selective aldosterone antagonists (eplerenone) alone versus ACEi alone</h4> <section id="CD007004-sec-0087"> <h5 class="title">Hyperkalaemia</h5> <p>One cross‐over study reported hyperkalaemia (<a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>). Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0088"> <h5 class="title">Proteinuria</h5> <p>One cross‐over study reported proteinuria (<a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>). Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0089"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; death (any cause); cardiovascular events; eGFR; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria; blood pressure: serum potassium; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0090"> <h4 class="title">Selective aldosterone antagonists (eplerenone) alone versus ACEi plus ARB</h4> <section id="CD007004-sec-0091"> <h5 class="title">Hyperkalaemia</h5> <p>One cross‐over study reported hyperkalaemia (<a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>). Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0092"> <h5 class="title">Proteinuria</h5> <p>One cross‐over study reported proteinuria (<a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>). Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0093"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; death (any cause); cardiovascular events; eGFR; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria; blood pressure: serum potassium; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0094"> <h4 class="title">Selective aldosterone antagonists (eplerenone) plus ACEi or ARB (or both) versus ACEi or ARB (or both) </h4> <section id="CD007004-sec-0095"> <h5 class="title">Hyperkalaemia</h5> <p>Selective aldosterone antagonists plus ACEi or ARB (or both) may increase the risk of hyperkalaemia (<a href="./references#CD007004-fig-0060" title="">Analysis 6.1</a> (2 studies, 500 participants): RR 1.62, 95% CI 0.66 to 3.95; I<sup>2</sup> = 0%; low certainty evidence). </p> </section> <section id="CD007004-sec-0096"> <h5 class="title">Proteinuria</h5> <p>Six studies reported proteinuria, however data could not be meta‐analysed (<a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>; <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>). </p> </section> <section id="CD007004-sec-0097"> <h5 class="title">Blood pressure</h5> <p>Four studies reported blood pressure, however data could not be meta‐analysed (<a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a>; <a href="./references#CD007004-bbs2-0013" title="EpsteinM , BuckalewV , MartinezF . Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]. American Journal of Hypertension2002;15(4 Suppl 1):24A. [CENTRAL: CN-00689079] ">Epstein 2002</a>; <a href="./references#CD007004-bbs2-0014" title="EpsteinM , WeinbergerM , LewinA , MartinezF , HeW , KrauseS . The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]. Journal of the American Society of Nephrology2003;14(Nov):6A. [CENTRAL: CN-00550622] EpsteinM , WilliamsGH , WeinbergerM , LewinA , KrauseS , MukherjeeR , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN2006;1(5):940-51. [MEDLINE: 17699311]">Epstein 2006</a>; <a href="./references#CD007004-bbs2-0022" title="HaykalWJ , KuryataOV , FrolovaEO , ShvedenkoOO . The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi257. [CENTRAL: CN-01657693] ">Haykal 2007</a>). </p> </section> <section id="CD007004-sec-0098"> <h5 class="title">Glomerular filtration rate</h5> <p>One cross‐over study (<a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>) reported no difference in eGFR between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0099"> <h5 class="title">Serum potassium</h5> <p>One cross‐over study (<a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>) reported no difference in serum potassium between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0100"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; death (any cause); cardiovascular events; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0101"> <h4 class="title">Selective aldosterone antagonists (eplerenone) plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate </h4> <section id="CD007004-sec-0102"> <h5 class="title">Proteinuria</h5> <p><a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a> reported urine protein excretion was significantly reduced after four weeks of eplerenone while it increased in the comparator group. We could not conduct a meta‐analysis as additional data could not be obtained from the investigators. </p> </section> <section id="CD007004-sec-0103"> <h5 class="title">Blood pressure</h5> <p><a href="./references#CD007004-bbs2-0011" title="CohenDL , SterlingK , TownsendRR . Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]. Journal of the American Society of Nephrology2010;21(Abstracts):936A. [CENTRAL: CN-01657694] CohenDL , SterlingKA , TownsendRR . Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]. Journal of Clinical Hypertension2011;13(4 Suppl 1):A116. [CENTRAL: CN-01657695] ">Cohen 2010</a> reported systolic blood pressure was reduced by 9.7 ± 6.4 mmHg in the eplerenone group and by 1.0 ± 5.4 mmHg in the ACEi/ARB plus isosorbide group at 4 weeks. No data were available about diastolic blood pressure. We could not conduct a meta‐analysis as additional data could not be obtained from the investigators. </p> </section> <section id="CD007004-sec-0104"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; hyperkalaemia; death (any cause); cardiovascular events; eGFR; doubling of SCr; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria: serum potassium; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0105"> <h4 class="title">Non‐steroidal mineralocorticoid antagonists (finerenone) versus selective aldosterone antagonist (eplerenone) </h4> <section id="CD007004-sec-0106"> <h5 class="title">Hyperkalaemia</h5> <p><a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a> reported no difference in the risk of hyperkalaemia between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0107"> <h5 class="title">Death</h5> <p><a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a> reported no difference in the risk of death between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0108"> <h5 class="title">Glomerular filtration rate</h5> <p><a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a> reported no significant change in GFR from baseline in either group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0109"> <h5 class="title">Doubling of serum creatinine</h5> <p><a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a> reported no difference in the risk of doubling of SCr between the two groups. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0110"> <h5 class="title">Blood pressure</h5> <p><a href="./references#CD007004-bbs2-0004" title="FilippatosG , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal2016;37(27):2105-14. [MEDLINE: 27130705]PittB , AnkerSD , BohmM , GheorghiadeM , KoberL , KrumH , et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure2015;17(2):224-32. [MEDLINE: 25678098]SatoN , AjiokaM , YamadaT , KatoM , MyoishiM , YamadaT , et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circulation Journal2016;80(5):1113-22. [MEDLINE: 27074824]">ARTS‐HF 2015</a> reported no significant change in systolic blood pressure from baseline in either group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0111"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; cardiovascular events; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria: serum potassium; acute kidney injury; gynaecomastia; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0112"> <h4 class="title">Non‐selective aldosterone antagonists (spironolactone) plus ACEi and ARB versus ACEi</h4> <section id="CD007004-sec-0113"> <h5 class="title">Hyperkalaemia</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> reported hyperkalaemia in 9/64 patients in the spironolactone plus ACEi and ARB group and 3/64 patients in the ACEi group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0114"> <h5 class="title">Proteinuria</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> reported proteinuria was significantly lower in the spironolactone plus ACEi and ARB group compared to ACEi group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0115"> <h5 class="title">Glomerular filtration rate</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> reported eGFR was lower in ACEi group compared to the spironolactone plus ACEi and ARB group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0116"> <h5 class="title">Blood pressure</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> systolic and diastolic blood pressure was lower in the spironolactone plus ACEi and ARB group compared to the ACEi group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0117"> <h5 class="title">Serum potassium</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> reported serum potassium was lower in the ACEi group compared to the spironolactone plus ACEi and ARB group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0118"> <h5 class="title">Gynaecomastia</h5> <p><a href="./references#CD007004-bbs2-0006" title="BianchiS , BigazziR , CampeseVM . Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. American Journal of Kidney Diseases2010;55(4):671-81. [MEDLINE: 20097461]">Bianchi 2010</a> reported gynaecomastia in 9/64 patients in the spironolactone plus ACEi and ARB group and 0/64 patients in the ACEi group. Meta‐analysis was not performed. </p> </section> <section id="CD007004-sec-0119"> <h5 class="title">Other outcomes</h5> <p>Data for the following outcomes were not extractable in a format required for inclusion in analyses or not reported in the available studies: kidney failure; death; cardiovascular events; progression from micro‐ to macroalbuminuria; regression from macro‐ to microalbuminuria and regression from micro‐ to normoalbuminuria: acute kidney injury; fatigue; and falls. </p> </section> </section> <section id="CD007004-sec-0120"> <h4 class="title">Publication bias</h4> <p>Overall, there were sufficient data and lack of statistical heterogeneity for the outcomes eGFR and hyperkalaemia for the comparison of aldosterone antagonists and placebo or standard care. There was no evidence of small study effects in the analysis of eGFR (<a href="#CD007004-fig-0009">Figure 9</a>) or hyperkalaemia (<a href="#CD007004-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD007004-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of GFR [mL/min/1.73 m²]." data-id="CD007004-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of GFR [mL/min/1.73 m²]. </p> </div> </div> </div> <div class="figure" id="CD007004-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of hyperkalaemia." data-id="CD007004-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of hyperkalaemia. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007004-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007004-sec-0121"></div> <section id="CD007004-sec-0122"> <h3 class="title" id="CD007004-sec-0122">Summary of main results</h3> <p>In this review of the evidence for aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of CKD, 44 studies involving 5637 participants were available. Studies included follow‐up for generally three to 12 months. Compared to ACEI or ARB (or both), the addition of an aldosterone antagonist has uncertain effects on progression to kidney failure, major cardiovascular events, and death (any cause) while probably doubling the risk of hyperkalaemia and probably increasing risk of acute kidney injury and gynaecomastia in adults who have proteinuric CKD stages 1 to 4. Aldosterone blockade may reduce proteinuria and kidney function in addition to co‐intervention with ACEi or ARB over a median treatment duration of 3.5 months and may lower systolic blood pressure but had little or no effect on diastolic blood pressure. Aldosterone antagonists appeared to lower systolic pressure to a greater extent in non‐diabetic kidney disease compared to diabetic kidney disease. While aldosterone antagonists appeared to lower proteinuria in diabetic kidney disease, its anti‐proteinuric effect in non‐diabetic kidney disease is less certain. Compared to diuretics, non‐selective aldosterone antagonists (spironolactone or canrenone) had uncertain effects on proteinuria and systolic blood pressure but may increase serum potassium. Furthermore, data comparing aldosterone antagonists to calcium channel blockers or nitrates, and data for treatment effects of selective aldosterone antagonists (eplerenone) and non‐steroidal mineralocorticoid antagonists (finerenone) were sparse leading to serious imprecision in treatment estimates or a lack of sufficient data for meta‐analysis. </p> </section> <section id="CD007004-sec-0123"> <h3 class="title" id="CD007004-sec-0123">Overall completeness and applicability of evidence</h3> <p>This review examined the evidence, updated to 2020, for the benefits of aldosterone antagonists in proteinuric CKD focusing on patient‐centred outcomes (including kidney failure, death (any cause), and major cardiovascular events) and potential harms (including hyperkalaemia, acute kidney injury, and gynaecomastia). Similar to the previous versions of this review in 2009 and 2014, evidence for aldosterone antagonists in preventing the progression of CKD has allowed primarily the evaluation of surrogate outcomes such as proteinuria and blood pressure rather than patient‐centred outcomes. The Standardised Outcomes in Nephrology (SONG) initiative aims to establish a set of core outcomes based on the shared priorities of patients, caregivers, clinicians, researchers, and policy makers. The SONG‐Glomerular Disease core outcomes are being established and will be essential in standardising outcome reporting in future studies (<a href="./references#CD007004-bbs2-0118" title="CarterSA , LightstoneL , CattranD , BaggaA , BarbourSJ , BarrattJ , et al. Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International2019;95(6):1280–3. [MEDLINE: 31122702]">SONG‐GD 2019</a>). The clinical relevance of proteinuria to predict progression of CKD has been shown in multiple studies where reduction in proteinuria was associated with reduced decline in eGFR and kidney failure for both non‐diabetic kidney disease (<a href="./references#CD007004-bbs2-0078" title="Wright JT Jr, BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.[Erratum in: JAMA. 2006 Jun 21;295(23):2726]. Journal of the American Medical Association2002;288(19):2421-31. [MEDLINE: 12435255]">AASK 2002</a>; <a href="./references#CD007004-bbs2-0110" title='RuggenentiP , PernaA , MosconiL , PisoniR , RemuzziG . Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney International1998;53(5):1209–16. [MEDLINE: 9573535]'>REIN 1998</a>) and diabetic kidney disease (<a href="./references#CD007004-bbs2-0096" title="AtkinsRC , BrigantiEM , LewisJB , HunsickerLG , BradenG , deCrespignyPJ , et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. American Journal of Kidney Diseases2004;45(2):281-7. [MEDLINE: 15685505]">IDNT 2004</a>; <a href="./references#CD007004-bbs2-0111" title="BrennerBM , CooperME , deZeeuwD , KeaneWF , MitchWE , ParvingHH , et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine2001;345(12):861-9. [MEDLINE: 11565518]">RENAAL 2001</a>). However, it is ultimately a surrogate outcome and it remains uncertain whether reduction in proteinuria with aldosterone antagonists in addition to ACEi or ARB reduces risk of kidney failure, death (any cause), and major cardiovascular events. Furthermore, reported measures of proteinuria in the included studies were heterogeneous necessitating the use of SMD, which is difficult to apply clinically since it summarises the intervention effect in each study relative to the standard deviation observed in each study. The use of SMD also assumes differences in standard deviations amongst the studies reflect differences in the measurement scales of proteinuria rather than differences in the study populations, which may not be true due to differences in severity of CKD, cause of CKD and co‐interventions between studies. Caution should also be advised since aldosterone antagonists may increase risk of hyperkalaemia, and probably increased risks of acute kidney injury and gynaecomastia. The risk of hyperkalaemia reported in the included studies may be influenced by the dose of spironolactone used, mostly 25 mg/day or higher with no studies evaluating lower dose spironolactone (e.g. 12.5 mg/day), which could reduce proteinuria and minimise risk of hyperkalaemia in the CKD population. </p> <p>Study duration was mostly between three to 12 months, which limits the ability of the current evidence to inform clinical practice on hard endpoints such as kidney failure, death (any cause) and major cardiovascular events, and on long‐term safety. Few studies specified baseline kidney function and proteinuria; therefore, it is unclear whether aldosterone antagonists had different efficacy and safety based on the severity of underlying kidney disease or proteinuria. A recent phase II RCT showed spironolactone did not increase risk of hyperkalaemia in maintenance haemodialysis patients compared to placebo until dosages of 50 mg/day or higher (<a href="./references#CD007004-bbs2-0119" title="CharytanDM , HimmelfarbJ , IkizlerTA , RajDS , HsuJY , LandisJR , et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International2019;95(4):973-82. [MEDLINE: 30473139]">SPin‐D 2019</a>). However, no effect on diastolic function assessed by Doppler echocardiography was detected in this small study (<a href="./references#CD007004-bbs2-0119" title="CharytanDM , HimmelfarbJ , IkizlerTA , RajDS , HsuJY , LandisJR , et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International2019;95(4):973-82. [MEDLINE: 30473139]">SPin‐D 2019</a>) and further phase III studies are needed to evaluate the safety and efficacy of aldosterone antagonists in kidney failure. </p> </section> <section id="CD007004-sec-0124"> <h3 class="title" id="CD007004-sec-0124">Quality of the evidence</h3> <p>The evidence identified in this review for the primary efficacy and safety outcomes (kidney failure and hyperkalaemia) was of very low to low certainty. This evidence for the effect of aldosterone antagonists on preventing kidney failure was downgraded primarily due to methodological limitations in the included studies and serious imprecision in estimated treatment effects. The evidence for the increased risk of hyperkalaemia due to aldosterone antagonists in CKD was downgraded primarily due to study limitations. </p> <p>Most studies enrolled few patients and were powered to observe differences in surrogate end points rather than patient‐focused outcomes. Ten studies had a cross‐over design (<a href="./references#CD007004-bbs2-0007" title="BoesbyL , Elung-JensenT , KlausenTW , StrandgaardS , KamperAL . Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE [Electronic Resource]2011;6(11):e26904. [MEDLINE: 22073219]BoesbyL , Elung-JensenT , StrandgaardS , KamperA . Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01912397] ">Boesby 2011</a>; <a href="./references#CD007004-bbs2-0029" title="MoralesE , HuertaA , GutierrezE , GutierrezSE , SeguraJ , PragaM . The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? [Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz]. Nefrologia2009;29(5):421-9. [MEDLINE: 19820754]MoralesE , HuertaA , Gutierrez-MilletV , GutierrezE , Gutierrez-SolisE , HernandezE , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]. NDT Plus2009;2(Suppl 2):ii882. [CENTRAL: CN-01657690] MoralesE , HuertaA , Gutierrez-SolisE , GutierrezE , PolancoN , Gutierrez-MilletV , et al. Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):549A. [CENTRAL: CN-00790676] ">Morales 2009</a>; <a href="./references#CD007004-bbs2-0030" title="MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , FernandezC , et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. Kidney International2015;88(6):1434-41. [MEDLINE: 26308670]MoralesE , CaroJ , GutierrezE , SevillanoA , AunonP , PragaM . Crossover randomized clinical trial to evaluate the albuminuric effect of three different types of diuretics (spironolactone, hydroclorothiazide and hydroclorothiazide+amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: SP309]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii482. [EMBASE: 72207635]MoralesE , EspadaPJ , Gutierrez-MartinezE , PragaM . Crossover randomised clinical trial to evaluate the antialbuminuric effect of three different types of diuretics (spironolactone, hydrochlorothiazide and hydrochlorothiazide + amiloride) on top of RAAS blockade in proteinuric nephropathies [abstract no: TH-PO655]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):257A. ">Morales 2015</a>; <a href="./references#CD007004-bbs2-0031" title="NielsenS , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomised placebo-controlled crossover study [abstract no: 1099]. Diabetologia2011;54(Suppl 1):S445. [EMBASE: 70563244]NielsenS , PerssonF , FrandsenE , SugayaT , ZdunekDW , PedersenK , et al. Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]. Journal of the American Society of Nephrology2011;22(Abstracts):238A. [CENTRAL: CN-01912458] NielsenSE , PerssonF , FrandsenE , SugayaT , HessG , ZdunekD , et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabetic Medicine2012;29(8):e184-90. [MEDLINE: 22268920]">Nielsen 2012</a>; <a href="./references#CD007004-bbs2-0033" title="RossingK , SchjoedtKJ , SmidtUM , BoomsmaF , ParvingHH . Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care2005;28(9):2106-12. [MEDLINE: 16123474]">Rossing 2005</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0035" title="SchjoedtKJ , RossingK , JuhlTR , BoomsmaF , RossingP , ParvingHH . Beneficial impact of spironolactone in diabetic nephropathy. Kidney International2005;68(6):2829-36. [MEDLINE: 16316360]SchjoedtKJ , RossingK , TarnowL , ParvingH . Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]. Journal of the American Society of Nephrology2005;16(Abstracts):57A. [CENTRAL: CN-00689347] ">Schjoedt 2005</a>; <a href="./references#CD007004-bbs2-0036" title="SmolenE , NowickiM . Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv386. [CENTRAL: CN-00716094] ">Smolen 2006</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>, <a href="./references#CD007004-bbs2-0040" title="LizakowskiS , RutkowskiP , TylickiL , RenkeM , SulikowskaB , DonderskiR , et al. The effect of various types of the renin-angiotensin-aldosteron system blockade on proteinuria in chronic non-diabetic kidney disease: a double-blind cross-over randomised controlled trial [abstract no: FP112]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii109. [EMBASE: 70765606]LizakowskiS , TylickiL , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polskie Archiwum Medycyny Wewnetrznej2013;123(5):221-7. [MEDLINE: 23615633]TylickiL , LizakowskiS , RutkowskiP , RenkeM , SulikowskaB , HeleniakZ , et al. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?Kidney &amp; Blood Pressure Research2012;36(1):335-43. [MEDLINE: 23235363]">Tylicki 2012</a>), none of which reported on endpoints at the completion of each study phase to enable inclusion into the meta‐analysis. The majority of studies did not adequately report study methods, such as the methods of allocation concealment and blinding of outcome assessment, sufficient to assess study quality. For most studies, the study protocol was not available to assess selective reporting of outcomes. Of the 15 studies reporting systolic blood pressure in the comparison between aldosterone antagonists and placebo or standard care, only six studies defined the method of measuring blood pressure (<a href="./references#CD007004-bbs2-0008" title="BoesbyL , Elung-JensenT , StrandgaardS , KamperAL . Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. PLoS ONE [Electronic Resource]2013;8(5):e64549. [MEDLINE: 23704994]">Boesby 2013</a>; <a href="./references#CD007004-bbs2-0012" title="CabreraSE , EdwardsNC , SteedsRP , TownendJN , FerroCJ . Spironolactone increases serum uric acid levels in patients with chronic kidney disease. Journal of Human Hypertension2014;28(3):210-1. [MEDLINE: 23863804]EdwardsNC , FerroCJ , KirkwoodH , ChueCD , YoungAA , StewartPM , et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology2010;106(10):1505-11. [MEDLINE: 21059444]EdwardsNC , SteedsRP , ChueCD , StewartPM , FerroCJ , TownendJN . The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. British Journal of Clinical Pharmacology2012;73(3):447-54. [MEDLINE: 21950312]EdwardsNC , SteedsRP , StewartPM , FerroCJ , TownendJN . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology2009;54(6):505-12. [MEDLINE: 19643310]HammerF , EdwardsNC , HughesBA , SteedsRP , FerroCJ , TownendJN , et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology2010;73(5):566-72. [MEDLINE: 20550533]">CRIBS II 2009</a>; <a href="./references#CD007004-bbs2-0018" title="FurumatsuY , NagasawaY , TomidaK , MikamiS , KanekoT , OkadaN , et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research - Clinical &amp; Experimental2008;31(1):59-67. [MEDLINE: 18360019]FurumatsuY , ShojiT , HayashiD , TomidaK , KanekoT , TsubakiharaY , et al. Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone: one year follow up [abstract no: SU-FC069]. Journal of the American Society of Nephrology2004;15(Oct):58A. [CENTRAL: CN-00653797] FurumatsuY , ShojiT , TomidaK , MikamiS , KanekoT , TogawaM , et al. Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]. Journal of the American Society of Nephrology2003;14(Suppl S):762A. [CENTRAL: CN-00653796] ">Furumatsu 2008</a>; <a href="./references#CD007004-bbs2-0019" title="GuneyI , SelcukNY , AltintepeL , AtalayH , BasaraliMK , BuyukbasS . Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Renal Failure2009;31(9):779-84. [MEDLINE: 19925284]">Guney 2009</a>; <a href="./references#CD007004-bbs2-0034" title="SaklayenM , GyebiL , TasosaJ , YapJ . Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]. Journal of the American Society of Nephrology2006;17(Abstracts):157A. [CENTRAL: CN-00615896] SaklayenMG , GyebiLK , TasosaJ , YapJ . Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. Journal of Investigative Medicine2008;56(4):714-9. [MEDLINE: 18382267]">Saklayen 2008</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>). Of the five studies reporting acute kidney injury, only one study specified a definition (<a href="./references#CD007004-bbs2-0002" title="PittB , FilippatosG , GheorghiadeM , KoberL , KrumH , PonikowskiP , et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure2012;14(6):668-75. [MEDLINE: 22562554]PittB , KoberL , PonikowskiP , GheorghiadeM , FilippatosG , KrumH , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal2013;34(31):2453-63. [MEDLINE: 23713082]">ARTS 2012</a>). Of the four studies reporting gynaecomastia, none provided a definition. </p> </section> <section id="CD007004-sec-0125"> <h3 class="title" id="CD007004-sec-0125">Potential biases in the review process</h3> <p>Our review has a number of strengths and weaknesses. The review examined aldosterone antagonists for their benefits on patient‐centred outcomes and potential harms, and was conducted with a peer‐reviewed protocol, a systematic search of electronic databases including the Cochrane Kidney and Transplant Specialised Register of studies, data extraction and analysis and study quality assessment by two independent authors, and adjudication of evidence certainty using the GRADE process. The key limitation of the review is the data provided by available studies. First, long‐term data for the effects of aldosterone antagonists on major patient‐centred outcomes including death, kidney failure, and major cardiovascular events were absent or sparse, with most studies primarily focused on surrogate outcomes such as proteinuria. In the cross‐over studies and many other RCTs, outcomes were not reported in ways that could be extracted, which lowered confidence in the results. Whilst authors of all studies were contacted, most no longer had access to the raw data. Second, the duration of follow‐up in most studies was likely sub‐optimal for detecting these hard endpoints. The 10‐year risk of kidney failure in 50 year old persons with an eGFR of 30 to 44 mL/min/1.73 m² is 11% to 21% depending on gender and only 1% to 2% with eGFR 45 to 59 mL/min/1.73 m² (<a href="./references#CD007004-bbs2-0125" title="TurinTC , TonelliM , MannsBJ , AhmedSB , RavaniP , JamesM , et al. Lifetime risk of ESRD. Journal of the American Society of Nephrology2012;23(9):1569-78. [MEDLINE: 22904351]">Turin 2012</a>), whilst the 25‐year risk of kidney failure in persons with an eGFR less than 60 mL/min/1.73 m² and 2+ proteinuria or higher on urinalysis is 41% compared to 6% for 1+ proteinuria and 4% in the absence of proteinuria (<a href="./references#CD007004-bbs2-0097" title="IshaniA , GranditsGA , GrimmRH , SvendsenKH , CollinsAJ , PrineasRJ , et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. Journal of the American Society of Nephrology2006;17(5):1444-52. [MEDLINE: 16611715]">Ishani 2006</a>). Overall, in our systematic review of persons with CKD and variable levels of proteinuria, the median follow‐up of three months in the included studies is likely sub‐optimal for detecting the development of kidney failure. Third, data on stage 5 CKD were not available in the included studies. Finally, there was a significant heterogeneity between studies in treatment effects on proteinuria. Although we explored causes of heterogeneity by type of kidney disease and study duration, insufficient data were available for testing the effect of baseline kidney function and proteinuria. Treatment duration and other factors may therefore modify the treatment effects we observed. </p> </section> <section id="CD007004-sec-0126"> <h3 class="title" id="CD007004-sec-0126">Agreements and disagreements with other studies or reviews</h3> <p>In this systematic review, aldosterone antagonist therapy in addition to ACEi or ARB therapy was found to reduce proteinuria in participants with stage 1‐4 proteinuric CKD, increase risk of hyperkalaemia and decline in eGFR, but had no detectable effect on kidney failure, cardiovascular events, and death, which is consistent with existing literature. One previous systematic review of aldosterone antagonists in both diabetic and non‐diabetic CKD found a reduction in proteinuria, eGFR, systolic and diastolic blood pressure, and an increased risk of hyperkalaemia (<a href="./references#CD007004-bbs2-0085" title="CurrieG , TaylorAH , FujitaT , OhtsuH , LindhardtM , RossingP , et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology2016;17(1):127. [MEDLINE: 27609359]">Currie 2016</a>). Similar to our review, <a href="./references#CD007004-bbs2-0085" title="CurrieG , TaylorAH , FujitaT , OhtsuH , LindhardtM , RossingP , et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology2016;17(1):127. [MEDLINE: 27609359]">Currie 2016</a>l could not conclude the effect of aldosterone antagonists on kidney failure, cardiovascular events and death, due to underreporting of these outcomes in included studies. However, apart from hyperkalaemia, other potential harms of aldosterone antagonists such as acute kidney injury and gynaecomastia were not explored. Furthermore, our review found the effect of aldosterone antagonists on diastolic blood pressure were uncertain. The discordance between the current Cochrane review and <a href="./references#CD007004-bbs2-0085" title="CurrieG , TaylorAH , FujitaT , OhtsuH , LindhardtM , RossingP , et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology2016;17(1):127. [MEDLINE: 27609359]">Currie 2016</a> is possibly explained by the inclusion of more recent trials in our review. Four other previous systematic reviews of aldosterone antagonists in diabetic CKD reported a reduction in proteinuria, and systolic and diastolic blood pressure, an increased risk of hyperkalaemia, and a reduction or unclear effect on eGFR (<a href="./references#CD007004-bbs2-0095" title="HouJ , XiongW , CaoL , WenX , LiA . Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clinical Therapeutics2015;37(9):2086-103. [MEDLINE: 26254276]">Hou 2015</a>; <a href="./references#CD007004-bbs2-0102" title="MavrakanasTA , GarianiK , MartinPY . Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. A systematic review. European Journal of Internal Medicine2014;25(2):173–6. [MEDLINE: 24315413]">Mavrakanas 2014</a>; <a href="./references#CD007004-bbs2-0123" title="SunLJ , SunYN , ShanJP , JiangGR . Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. Journal of Diabetes Investigation2017;8(4):609-18. [MEDLINE: 28107779]">Sun 2017</a>; <a href="./references#CD007004-bbs2-0124" title="TakahashiS , KatadaJ , DaidaH , KitamuraF , YokoyamaK . Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. Journal of Human Hypertension2016;30(9):534–42. [MEDLINE: 26674759]">Takahashi 2016</a>). One review (<a href="./references#CD007004-bbs2-0124" title="TakahashiS , KatadaJ , DaidaH , KitamuraF , YokoyamaK . Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. Journal of Human Hypertension2016;30(9):534–42. [MEDLINE: 26674759]">Takahashi 2016</a>) performed meta‐analyses on blood pressure and serum potassium but not on the kidney outcomes such as proteinuria and eGFR, despite an adequate number of included studies, decreasing the strengths of its conclusions due to potential selective reporting bias. One review (<a href="./references#CD007004-bbs2-0102" title="MavrakanasTA , GarianiK , MartinPY . Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy. A systematic review. European Journal of Internal Medicine2014;25(2):173–6. [MEDLINE: 24315413]">Mavrakanas 2014</a>) did not perform a meta‐analysis due to the heterogeneous reporting of outcomes in the limited number of included studies, and did not specify risk of bias assessment by two independent authors, limiting the strength of its conclusions. None of the four reviews on diabetic CKD examined patient‐centred efficacy outcomes such as kidney failure, major cardiovascular events, or death. </p> <p>The results of our review also agree with existing RCTs and review articles showing an increased risk of hyperkalaemia when spironolactone is combined with ACEi or ARB (or both) in individuals with heart failure (<a href="./references#CD007004-bbs2-0107" title="PhillipsCO , KashaniA , KoDK , FrancisG , KrumholzHM . Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Archives of Internal Medicine2007;167(18):1930-6. [MEDLINE: 17923591]">Phillips 2007</a>; <a href="./references#CD007004-bbs2-0060" title="Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology1996;78(8):902-7. [MEDLINE: 8888663]GlickHA , OrzolSM , TooleyJF , RemmeWJ , SasayamaS , PittB . Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovascular Drugs &amp; Therapy2002;16(1):53-9. [MEDLINE: 12085979]HaubenM , ReichL , GerritsCM , MadiganD . Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Safety2007;30(12):1143-9. [MEDLINE: 18035866]PittB , ZannadF , RemmeWJ , CodyR , CastaigneA , PerezA , et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine1999;341(10):709-17. [MEDLINE: 10471456]PittD . ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal1995;16 Suppl N:107-10. [MEDLINE: 8682055]RousseauMF , GurneO , DuprezD , Van MieghemW , RobertA , AhnS , et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.[Erratum in: J Am Coll Cardiol. 2003 Nov 19;42(10):1865]. Journal of the American College of Cardiology2002;40(9):1596-601. [MEDLINE: 12427411]SchwingerRH . The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study [Der Aldosteronantagonist Spironolacton verlangert das Uberleben chronisch herzinsuffizienter Patienten. Ergebnisse der RALES-Studie]. Deutsche Medizinische Wochenschrift1999;124(34-35):987-8. [MEDLINE: 10488324]VardenyO , WuDH , DesaiA , RossignolP , ZannadF , PittB , et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). Journal of the American College of Cardiology2012;60(20):2082-9. [MEDLINE: 23083787]WittesJ , PalenskyJ , AsnerD , JulianD , BoisselJP , FurbergCD , et al. Experience collecting interim data on mortality: an example from the RALES study. Current Controlled Trials in Cardiovascular Medicine2001;2(1):59-62. [MEDLINE: 11806773]ZannadF , AllaF , DoussetB , PerezA , PittB . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.[Erratum in: Circulation 2001 Jan 23;103(3):476]. Circulation2000;102(22):2700-6. [MEDLINE: 11094035]">RALES 1995</a>). There is good evidence that ACEi or ARBs reduce progression of CKD to kidney failure requiring dialysis or transplantation by approximately 20% and have cardioprotective effects for adults with diabetic or non‐diabetic CKD (<a href="./references#CD007004-bbs2-0112" title="deZeeuwD , RemuzziG , ParvingHH , KeaneWF , ZhangZ , ShahinfarS , et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International2004;65(6):2309-20. [MEDLINE: 15149345]">RENAAL 2004</a>; <a href="./references#CD007004-bbs2-0121" title="StrippoliGF , CraigM , SchenaFP , CraigJC . Antihypertensive agents for primary prevention of diabetic nephropathy. Journal of the American Society of Nephrology2005;16(10):3081-91. [MEDLINE: 16135776]">Strippoli 2005</a>; <a href="./references#CD007004-bbs2-0122" title="StrippoliGF , BonifatiC , CraigM , NavaneethanSD , CraigJC . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD006257. [DOI: 10.1002/14651858.CD006257]">Strippoli 2006</a>). Some patients treated with ACEi with or without ARB exhibit aldosterone escape (<a href="./references#CD007004-bbs2-0120" title="StaessenJ , LijnenP , FagardR , VerschuerenLJ , AmeryA . Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology1981;91(3):457-65. [MEDLINE: 7035596]">Staessen 1981</a>) and the addition of aldosterone antagonists has been shown to have anti‐fibrotic and antihypertensive effects in animal and human studies (<a href="./references#CD007004-bbs2-0104" title="NakhoulF , KhankinE , YaccobA , KawachiH , KarramT , AwaadH , et al. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. American Journal of Physiology - Renal Physiology2008;294(3):F628-37. [MEDLINE: 18094029]">Nakhoul 2008</a>; <a href="./references#CD007004-bbs2-0039" title="LarczynskiW , TylickiL , RutkowskiP , RenkeM , RutkowskiB . The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi259. [CENTRAL: CN-00653742] TylickiL , RutkowskiP , RenkeM , LarczynskiW , AleksandrowiczE , Lysiak-SzydlowskaW , et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases2008;52(3):486-93. [MEDLINE: 18423812]TylickiL , RutkowskiP , RenkeM , RutkowskiB . Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International2007;72(9):1164-5. [MEDLINE: 17943159]">Tylicki 2008</a>). However, our review was unable to conclude whether aldosterone antagonists in addition to ACEi or ARB (or both) had any effect on risk of kidney failure, major cardiovascular events, or death. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007004-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Mechanisms of cardiac and kidney damage induced by aldosterone excess" data-id="CD007004-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Mechanisms of cardiac and kidney damage induced by aldosterone excess</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007004-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007004-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007004-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Effect of aldosterone antagonists versus placebo or standard care on kidney failure" data-id="CD007004-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on kidney failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Effect of aldosterone antagonists versus placebo or standard care on hyperkalaemia" data-id="CD007004-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on hyperkalaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Effect of aldosterone antagonists versus placebo or standard care on proteinuria." data-id="CD007004-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on proteinuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Effect of aldosterone antagonists versus placebo or standard care on GFR [mL/min/1.73 m²]." data-id="CD007004-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Effect of aldosterone antagonists versus placebo or standard care on GFR [mL/min/1.73 m²]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of GFR [mL/min/1.73 m²]." data-id="CD007004-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of GFR [mL/min/1.73 m²]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of hyperkalaemia." data-id="CD007004-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison studies comparing aldosterone antagonist versus control for the study endpoint of hyperkalaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 1: Kidney failure" data-id="CD007004-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 1: Kidney failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 2: Hyperkalaemia" data-id="CD007004-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 2: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 3: Subgroup analysis: hyperkalaemia ‐ number of RAS inhibitors used" data-id="CD007004-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 3: Subgroup analysis: hyperkalaemia ‐ number of RAS inhibitors used </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0014"> <p> <div class="table" id="CD007004-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Hyperkalaemia data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nielsen 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two patients had severe hyperkalaemia (plasma potassium = 5.7 mmol/L). Four patients experienced light to moderate hyperkalaemia (plasma potassium = 5.0 to 5.4 mmol/L). Hyperkalaemia was mainly observed 2 weeks after the start of spironolactone treatment </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 4: Hyperkalaemia data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 5: Death" data-id="CD007004-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 5: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 6: Cardiovascular events" data-id="CD007004-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 6: Cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 7: Myocardial infarction" data-id="CD007004-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 7: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 8: Stroke" data-id="CD007004-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 8: Stroke </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 9: Proteinuria" data-id="CD007004-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 9: Proteinuria </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0020"> <p> <div class="table" id="CD007004-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone or spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean UACR decreased in all BAY 94‐8862 dose groups (geometric mean ratio versus baseline UACR 0.77 for 2.5 mg/day, 0.69 for 5 mg/day, 0.72 for 10 mg/day and 0.86 for 5 mg twice/day) and in the spironolactone group (geometric mean ratio versus baseline UACR 0.61), compared with a small increase in the placebo group (geometric mean ratio versus baseline UACR 1.04). No P value or CI reported </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐DN 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone plus ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean placebo‐corrected ratios of UACR at day 90 versus baseline in the finerenone 7.5, 10, 15, and 20 mg/day groups were 0.79 (90% CI, 0.68 to 0.91; P = .004), 0.76 (90% CI, 0.65 to 0.88; P = 0.001), 0.67 (90% CI, 0.58 to 0.77; P &lt; 0.001), and 0.62 (90% CI, 0.54 to 0.72; P &lt; 0.001), respectively </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chen 2018b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus irbesartan (low or high dose) versus irbesartan (low or high dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 72 weeks, UAER significant decreased in the spironolactone + high dose irbesartan group (‐30 μg/min) and spironolactone + low dose irbesartan group (‐23 μg/min) compared to low dose irbesartan group (‐15 μg/min) (P &lt; 0.05). However, UAER was significantly reduced in high dose irbesartan (‐30 μg/min) compared to spironolactone + low dose irbesartan (‐23 μg/min) (P &lt; 0.05) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urine protein excretion was reduced by 1.04 ± 0.4 g/24 h in the eplerenone and by 0.32 ± 0.2 g/24 h in the ACEi plus ARB group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2002</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UAE was reduced by 74% in the eplerenone and by 45% in the control group</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone treatment significantly reduced albuminuria from baseline as early as week 4 and continued throughout weeks 8 and 12. ACEi treatment did not result in any significant decrease from baseline in albuminuria </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EVALUATE 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi and/or ARB versus ACEi and/or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UACR reduced significantly more with eplerenone (‐17.3 mg/g) than placebo (+10.3 mg/g) (P = 0.0222) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haykal 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone treatment reduced proteinuria after 4 weeks. The effect continued throughout weeks 8 and 12 (P &lt; 0.001) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kato 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 8, spironolactone reduced proteinuria compared to control (UACR ‐519.7 ± 129.4 mg/g) (P = 0.001) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Koroshi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In comparison with the placebo group, proteinuria decreased by 42.3% (95% CI, P = 0.004) in the group assigned to spironolactone </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lv 2009a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 9 months therapy, proteinuria decreased significantly (1.25 ± 0.61 g/day at baseline, 0.85 ± 0.56 g/day at the 3rd month, 0.81 ± 0.61 g/day at the 6th month, and 0.64 ± 0.42 g/day, at the 9th month, P &lt; 0.05) in patients treated with spironolactone, while it didn't change in control group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mehdi 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ACEi versus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the 48 weeks of treatment, albuminuria (UACR) decreased significantly from baseline in the ARB (P = 0.001) and spironolactone (P &lt; 0.0001) groups but not in the placebo group (P = 0.08). At 48 weeks, the percentage change from the baseline was 24.6% (95% CI 54.8% to 25.9%) in those assigned to placebo, 38.2% (95% CI 59.3% to 5.9%) in those assigned to ARB, and 51.6% (95% CI 70.2% to 21.4%) in those assigned to spironolactone </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tokunaga 2008a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ARB versus ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone reduced proteinuria from 1.70 ± 1.12 g/g to 1.11 ± 1.13 g/g Cr (P &lt; 0.05) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 10: Proteinuria: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0021"> <p> <div class="table" id="CD007004-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Boesby 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albuminuria was significantly lower during the add‐on eplerenone period as compared with the control period with a 22% (95% CI 14 to 28, P &lt; 0.001), lower excretion. The mean 24 hour excretion was 1481 mg (95% CI 1192 to 1840) during the control period and 1163 mg (95% CI 921 to 1468) during add‐on eplerenone. No significant carry‐over, P = 0.3 or time effect, P = 0.3, was detected for the UAE </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nielsen 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During spironolactone treatment, urinary albumin excretion was reduced by 60% (21% to 80%) from 90 mg/24 h to 35 mg/24 h when compared with placebo (P = 0.01) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 11: Proteinuria data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0021">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 12: eGFR [mL/min/1.73 m²]" data-id="CD007004-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 12: eGFR [mL/min/1.73 m²] </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0023"> <p> <div class="table" id="CD007004-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>eGFR: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone or spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was a decrease in eGFR in all finerenone groups (mean change from baseline eGFR ranging ‐0.85 to ‐2.69 mL/min/1.73 m<sup>2</sup>) and the spironolactone group (‐6.70 mL/min/1.73 m<sup>2</sup>), compared with a small increase in the placebo group (0.87 mL/min/1.73 m<sup>2</sup>). However, the decrease in the spironolactone group was significantly greater than in all finerenone groups (P = 0.0002 to 0.0133) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐DN 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone plus ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was absolute decrease in eGFR in all finerenone groups (mean change from baseline eGFR ranging ‐1.9 to ‐3.9 mL/min/1.73 m<sup>2</sup>) as well as placebo (‐1.5 mL/min/1.73 m<sup>2</sup>). No P value was reported </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chen 2018b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus irbesartan (low or high dose) versus irbesartan (low or high dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 72 weeks, eGFR was lower in the spironolactone + high dose irbesartan group (‐3.8 mL/min/1.73 m<sup>2</sup>) compared to low dose irbesartan (‐0.3 mL/min/1.73 m<sup>2</sup>) and high dose irbesartan group (‐1.5 mL/min/1.73 m<sup>2</sup>) (P &lt; 0.05), but not significantly different in the spironolactone + low dose irbesartan group (‐0.6 mL/min/1.73 m<sup>2</sup>) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EVALUATE 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi and/or ARB versus ACEi and/or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR was significantly lower with eplerenone (‐4.6 mL/min/1.73 m<sup>2</sup>) than placebo (+0.47 mL/min/1.73 m<sup>2</sup>) (P = 0.0041) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kato 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 8, there was no difference in eGFR between spironolactone and control (‐3.2 ± 9.7 mL/min/1.73 m<sup>2</sup>) (P = 0.052) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lv 2009a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By the end of the 9th month, the monthly rate of decrease of eGFR was similar in the two groups (‐0.66 mL/min/1.73 m<sup>2</sup> in spironolactone group versus ‐0.94 mL/min/1.73 m<sup>2</sup> in control group, P = 0.28) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 13: eGFR: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0024"> <p> <div class="table" id="CD007004-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>eGFR data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nielsen 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant decline in GFR from 78 mL/min/1.73 m<sup>2</sup> to 72 mL/min/1.73 m<sup>2</sup> (P = 0.003) during spironolactone treatment </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 14: eGFR data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 15: Doubling serum creatinine" data-id="CD007004-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 15: Doubling serum creatinine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 16: Systolic BP" data-id="CD007004-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 16: Systolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 17: Diastolic BP" data-id="CD007004-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 17: Diastolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0028"> <p> <div class="table" id="CD007004-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone or spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone significantly decreased systolic BP (‐10.1 mmHg) at day 29 ± 2 compared with either placebo (‐3.1 mmHg, P = 0.0104) or all doses of finerenone (range ‐1.9 to ‐4.2 mmHg, P = 0.0023 to 0.0255) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐DN 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone plus ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP from baseline to day 90 decreased in all finerenone groups (placebo corrected least squares mean differences range from −2.8 to −5.1 mmHg). Decreases only significant in 15 mg daily and 20 mg daily groups </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chen 2018b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus irbesartan (low or high dose) versus irbesartan (low or high dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 72 weeks, there was no difference between systolic of diastolic BP between the spironolactone + high dose irbesartan group (change in systolic BP ‐24 mmHg, diastolic BP ‐14 mmHg) or spironolactone + low dose irbesartan (change in systolic BP ‐24 mmHg, diastolic BP ‐13 mmHg), compared to low dose irbesartan (change in systolic BP ‐23 mmHg, diastolic BP ‐13 mmHg) and high dose irbesartan group (change in systolic BP ‐24 mmHg, diastolic BP ‐14 mmHg) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP was reduced by 9.7 ± 6.4 mmHg in the eplerenone group and by 13.4 ± 14.9 mmHg in the ACEi plus ARB group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2002</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP was reduced by 21.8% and 20.4% in the eplerenone and control group respectively. Diastolic BP was reduced by 16.2% and 15% in the eplerenone and control group respectively </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both systolic and diastolic BP decreased at weeks 4, 8, and 12 in eplerenone and control groups. There were no significant differences in BP reduction between groups </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EVALUATE 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi and/or ARB versus ACEi and/or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP was lower with eplerenone (128.8 mmHg) than placebo (132.2 mmHg) (P = 0.0035). Diastolic BP was also lower with eplerenone (76.7 mmHg) than placebo (78.4 mmHg) (P &lt; 0.0370) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haykal 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both systolic and diastolic BP decreased in the two groups at weeks 4, 8 and 12 (P &lt; 0.001). BP reduction was slightly higher in eplerenone group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kato 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 8, there was no difference in blood pressure between spironolactone (systolic BP ‐2.68 ± 25.3 mmHg, diastolic BP ‐3.44 ± 14.3 mmHg) and control (no change but exact values not reported) (P value not reported) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 18: Blood pressure: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0029"> <p> <div class="table" id="CD007004-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Boesby 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic and diastolic BP was significantly lower during add‐on eplerenone treatment when compared to the control period. There was a significant reduction of systolic BP after 2 weeks of eplerenone treatment (P = 0.003). The diastolic BP was significantly reduced after 4 weeks of eplerenone treatment (P = 0.002), and there was a significant difference in diastolic BP between the treatment period and control period at the same time point (P = 0.004).There were no significant differences between diastolic BP at the end of the 2 periods. There were no significant carry‐over, P = 0.4 and P = 0.9, or time effects, P = 0.5 and P = 0.2 for systolic BP or diastolic BP </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nielsen 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant changes in diastolic and systolic BP after the placebo or spironolactone period </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 19: Blood pressure data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 20: Serum potassium" data-id="CD007004-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 20: Serum potassium </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0031"> <p> <div class="table" id="CD007004-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Potassium: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone or spironolactone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By day 29 ± 2, finerenone 10 mg/day and 5 mg twice/day showed significantly greater mean increases in serum potassium concentration from baseline than placebo<br/>(P = 0.02 and P = 0.0003, respectively) </p> <p>Finerenone: 5mg/day and 2.5 mg/day groups were not significantly different from placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐DN 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone plus ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potassium non‐significantly increased in all finerenone groups (absolute mean change from baseline to day 90 range 0.07 to 0.23) and non‐significantly decreased with placebo (‐0.004) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chen 2018b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus irbesartan (low or high dose) versus irbesartan (low or high dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 72 weeks, potassium was higher in the spironolactone + high dose irbesartan group (+ 0.5 mmol/L) compared to low dose irbesartan (+ 0.11 mmol/L) and high dose irbesartan group (+ 0.29 mmol/L) (P &lt; 0.05). Potassium was higher in the spironolactone + low dose irbesartan group (+ 0.27 mmol/L) compared to low dose irbesartan group (+ 0.11 mmol/L) (P &lt; 0.05) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EVALUATE 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi and/or ARB versus ACEi and/or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Potassium increased from baseline more with eplerenone (+0.17 mmol/L) than placebo (+0.02 mmol/L) (P = 0.0043) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lv 2009a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ACEi or ARB versus ACEi or ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone caused an increase in serum potassium after 9 months of treatment (from 3.8 ± 0.4 mEq/L to 4.1 ± 0.3 mEq/L, P = 0.029) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tokunaga 2008a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone + ARB versus ARB alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone produced a significant increase in serum potassium levels (from 4.31 ± 0.53 mmol/L to 4.67 ± 0.68 mmol/L, P &lt; 0.05) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 21: Potassium: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 22: Acute kidney injury" data-id="CD007004-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 22: Acute kidney injury </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 23: Gynaecomastia" data-id="CD007004-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 23: Gynaecomastia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 24: Subgroup analysis: proteinuria ‐ duration of follow‐up" data-id="CD007004-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 24: Subgroup analysis: proteinuria ‐ duration of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 25: Subgroup analysis: systolic BP ‐ duration of follow‐up" data-id="CD007004-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 25: Subgroup analysis: systolic BP ‐ duration of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 26: Subgroup analysis: diastolic BP ‐ duration of follow‐up" data-id="CD007004-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 26: Subgroup analysis: diastolic BP ‐ duration of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 27: Subgroup analysis: serum potassium ‐ duration of follow‐up" data-id="CD007004-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Aldosterone antagonist versus placebo/standard care (all studies), Outcome 27: Subgroup analysis: serum potassium ‐ duration of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 1: Proteinuria" data-id="CD007004-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 1: Proteinuria </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0039"> <p> <div class="table" id="CD007004-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hase 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus trichlormethiazide plus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 24, UAER decreased in both spironolactone group (‐57.6% from baseline) and trichlormethiazide group (‐48.4% from baseline) but there was no between group difference </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morales 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi versus hydrochlorothiazide plus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 4, 24 h urine protein decreased in both spironolactone group (median proteinuria 1.7 g to 1.5 g) and hydrochlorothiazide group (median proteinuria 1.7 g to 1.3 g) but there was no between group difference </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 2: Proteinuria: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0039">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0040"> <p> <div class="table" id="CD007004-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptive outcome data</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Smolen 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone verus hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At the start of treatment with spironolactone or hydrochlorothiazide, PCR was 1.65 ± 1.39 and 1.46 ± 1.28 g/g, respectively. After 8 weeks of treatment with spironolactone proteinuria was significantly reduced to 0.99 ± 1.03 g/g (P = 0.03; a decrease of 0.66 ± 0.64 g/g) but not after hydrochlorothiazide (1.28 ± 1.18 g/g; P = 0.35, a decrease of 0.18 ± 0.83 g/g) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 3: Proteinuria data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0040">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 4: eGFR [mL/min/1.73 m²]" data-id="CD007004-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 4: eGFR [mL/min/1.73 m²] </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0042"> <p> <div class="table" id="CD007004-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>GFR: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hase 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus trichlormethiazide plus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 24, eGFR decreased in both spironolactone group (‐9.3 mL/min/1.73 m<sup>2</sup> from baseline) and trichlormethiazide group (‐9.4 mL/min/1.73 m<sup>2</sup> from baseline) but there was no between group difference </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 5: GFR: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0042">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0043"> <p> <div class="table" id="CD007004-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>eGFR data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptive outcome data</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Smolen 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean baseline GFR was 94 ± 25 mL/min in the spironolactone and 95 ± 28 mL/min in the hydrochlorothiazide group. After treatment the GFR remained similar in the two groups (91 ± 28 mL/min versus 93 ± 29 mL/min respectively) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 6: eGFR data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0043">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 7: Diastolic BP" data-id="CD007004-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 7: Diastolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 8: Systolic BP" data-id="CD007004-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 8: Systolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0046"> <p> <div class="table" id="CD007004-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hase 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus trichlormethiazide plus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 24, systolic BP decreased in both spironolactone group (‐12 mmHg from baseline) and trichlormethiazide group (‐10 mmHg from baseline) but there was no between group difference. Diastolic BP also decreased in both spironolactone group (‐7 mmHg from baseline) and trichlormethiazide group (‐3 mmHg from baseline) and there was no between group difference </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 9: Blood pressure: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0046">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0047"> <p> <div class="table" id="CD007004-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptive outcome data</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Smolen 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone verus hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 24 h BP was similar at the start of treatment with spironolactone or hydrochlorothiazide (95.7 ± 10.2 and 95.6 ± 9.1 mmHg, respectively). Both drugs did not significantly influence the 24 h BP (post‐treatment values were 95.6 ± 10.4 and 96.4 ± 12.1 mmHg, respectively) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 10: Blood pressure data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 11: Serum potassium" data-id="CD007004-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 11: Serum potassium </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0049"> <p> <div class="table" id="CD007004-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Potassium: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hase 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone plus ACEi or ARB versus trichlormethiazide plus ACEi or ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At week 24, serum potassium increased in the spironolactone group (+ 0.3 mmol/L from baseline) but remained unchanged in the trichlormethiazide group (P = 0.035) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 12: Potassium: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0049">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0050"> <p> <div class="table" id="CD007004-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Potassium data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptive outcome data</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Smolen 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone verus hydrochlorothiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum potassium concentration was 4.23 ± 0.39 and 4.29 ± 0.37 mmol/L, in the spironolactone and hydrochlorothiazide group, respectively. It tended to increase in the spironolactone group after treatment (0.29 ± 0.39 mmol/L, P = 0.01) while it remained stable in the hydrochlorothiazide group (‐0.13 ± 0.4 mmol/L, P = 0.18) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 13: Potassium data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 14: Fatigue" data-id="CD007004-fig-0051" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor, Outcome 14: Fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0052"> <p> <div class="table" id="CD007004-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Takebayashi 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone versus amlodipine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone reduced UAE from 543.7 mg/g Cr (170 to 1146) to 376.7 mg/g Cr (135 to 794) (P = 0.003). UAE did not change in amlodipine group (P = 0.38) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Spironolactone versus calcium channel blockers, Outcome 1: Proteinuria: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0052">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Spironolactone versus calcium channel blockers, Outcome 2: Systolic BP" data-id="CD007004-fig-0053" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Spironolactone versus calcium channel blockers, Outcome 2: Systolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Spironolactone versus calcium channel blockers, Outcome 3: Diastolic BP" data-id="CD007004-fig-0054" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Spironolactone versus calcium channel blockers, Outcome 3: Diastolic BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Spironolactone versus calcium channel blockers, Outcome 4: Serum potassium" data-id="CD007004-fig-0055" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Spironolactone versus calcium channel blockers, Outcome 4: Serum potassium</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0056"> <p> <div class="table" id="CD007004-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Hyperkalaemia data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morales 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of patients in which serum potassium was above 5.5 mEq/L after treatment was 2/12 (16%) with ACEi (lisinopril) while none of the patients treated with eplerenone reached this level of potassium </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Eplerenone versus ACEi, Outcome 1: Hyperkalaemia data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0056">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0057"> <p> <div class="table" id="CD007004-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptive outcome data</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morales 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACEi (lisinopril) induced a reduction in proteinuria (11.3 ± 34.8%) which was not statistically significant with respect to baseline values (P = 0.158), while that induced by eplerenone (28.4 ± 31.6%) was significant with respect to baseline values (comparison P = 0.034) and to the lisinopril group (P = 0.034) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Eplerenone versus ACEi, Outcome 2: Proteinuria data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0057">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0058"> <p> <div class="table" id="CD007004-tblf-0020"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Hyperkalaemia data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morales 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of patients in which serum potassium was above 5.5 mEq/L after treatment was 2/12 (16%) with ACEi plus ARBs (lisinopril plus candesartan) while none of the patients treated with eplerenone reached this level of potassium </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Eplerenone versus ACEi plus ARB, Outcome 1: Hyperkalaemia data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0058">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0059"> <p> <div class="table" id="CD007004-tblf-0021"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Morales 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both eplerenone and the combination of ACEi plus ARB (lisinopril and candesartan) obtained a significant reduction of proteinuria from baseline (26.9 ± 30.6% and 28.4 ± 31.6%, P = 0.045 and P = 0.034 respectively) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Eplerenone versus ACEi plus ARB, Outcome 2: Proteinuria data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0059">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 1: Hyperkalaemia" data-id="CD007004-fig-0060" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 1: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0061"> <p> <div class="table" id="CD007004-tblf-0022"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urine protein excretion was reduced by 1.04 ± 0.4 g/24 h in the eplerenone and by 0.32 ± 0.2 g/24 h in the ACEi plus ARB group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2002</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UAE was reduced by 74% in the eplerenone and by 45% in the control group</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone treatment significantly reduced albuminuria from baseline as early as week 4 and continued throughout weeks 8 and 12. ACEi treatment did not result in any significant decrease from baseline in albuminuria </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haykal 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone treatment reduced proteinuria after 4 weeks. The effect continued throughout weeks 8 and 12 (P &lt; 0.001) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 2: Proteinuria: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0061">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0062"> <p> <div class="table" id="CD007004-tblf-0023"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Boesby 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Albuminuria was significantly lower during the add‐on eplerenone period as compared with the control period with a 22% (95% CI 14 to 28, P &lt; 0.001), lower excretion. The mean 24 h excretion was 1481 mg (95% CI 1192 to 1840) during the control period and 1163 mg (95% CI 921 to 1468) during add‐on eplerenone. No significant carry‐over, P = 0.3 or time effect, P = 0.3, was detected for the UAE </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tylicki 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus telmisartan 80 mg daily versus telmisartan 160 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the 24 week study period, albuminuria was higher in the eplerenone plus telmisartan 80 mg/day group versus telmisartan 160 mg/day group (mean UACR 707 mg/g (95% CI 502‐1204)) versus 525 mg/g (95% CI 318 to 763)) though statistical significance was not reported </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 3: Proteinuria data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0062">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0063"> <p> <div class="table" id="CD007004-tblf-0024"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>eGFR: data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tylicki 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus telmisartan 80 mg daily versus telmisartan 160 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the 24 week study period, there was no difference between eplerenone plus telmisartan 80 mg daily group versus telmisartan 160 mg daily in creatinine clearance (97.3 ± 8.1 mL/min versus 97.9 ± 8.3 mL/min) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 4: eGFR: data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0063">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0064"> <p> <div class="table" id="CD007004-tblf-0025"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB versus ACEi plus ARB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP was reduced by 9.7 ± 6.4 mmHg in the eplerenone group and by 13.4 ± 14.9 mmHg in the ACEi plus ARB group </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2002</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP was reduced by 21.8% and 20.4% in the eplerenone and control group respectively. Diastolic BP was reduced by 16.2% and 15% in the eplerenone and control group respectively </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Epstein 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both systolic and diastolic BP decreased in at weeks 4, 8, and 12 in eplerenone and control groups. There were no significant differences in BP reduction between groups </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haykal 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi versus ACEi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both systolic and diastolic BP decreased in the two groups at weeks 4, 8 and 12 (P &lt; 0.001). BP reduction was slightly higher in eplerenone group </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 5: Blood pressure: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0064">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0065"> <p> <div class="table" id="CD007004-tblf-0026"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Boesby 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic and diastolic BP was significantly lower during add‐on eplerenone treatment when compared to the control period. There was a significant reduction of systolic BP after 2 weeks of eplerenone treatment (P = 0.003). The diastolic BP was significantly reduced after 4 weeks of eplerenone treatment (P = 0.002), and there was a significant difference in diastolic BP between the treatment period and control period at the same time point (P = 0.004).There were no significant differences between diastolic BP at the end of the 2 periods. There were no significant carry‐over, P = 0.4 and P = 0.9, or time effects, P = 0.5 and P = 0.2 for systolic BP or diastolic BP </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tylicki 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus telmisartan 80 mg daily versus telmisartan 160 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the 24 week study period, there was no difference between eplerenone plus telmisartan 80 mg daily group versus telmisartan 160 mg daily for both systolic BP (121.5 ± 2.6 mmHg versus 120.6 ± 2.4 mmHg) and diastolic BP (76.6 ± 1.9 mmHg versus 75.8 ± 2.0 mmHg) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 6: Blood pressure data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0065">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0066"> <p> <div class="table" id="CD007004-tblf-0027"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Serum potassium: data from cross‐over studies</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tylicki 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus telmisartan 80 mg daily versus telmisartan 160 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During the 24 week study period, there was no difference between eplerenone plus telmisartan 80 mg/day group versus telmisartan 160 mg/day in serum potassium (4.28 ± 0.08 mmol/L versus 4.45 ± 0.01 mmol/L) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both), Outcome 7: Serum potassium: data from cross‐over studies </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0066">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0067"> <p> <div class="table" id="CD007004-tblf-0028"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus isosorbide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urine protein excretion was reduced by 1.04 ± 0.4 g/24 h in the eplerenone group but increased in the ACEi/ARB plus isosorbide group by 0.2 ± 0.3 g/24 h </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate, Outcome 1: Proteinuria: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0067">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0068"> <p> <div class="table" id="CD007004-tblf-0029"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Systolic BP: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cohen 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus isosorbide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic blood pressure was reduced by 9.7 ± 6.4 mm Hg in the eplerenone group and by 1.0 ± 5.4 mm Hg in the ACEi/ARB plus isosorbide group </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate, Outcome 2: Systolic BP: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0068">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Finerenone versus eplerenone, Outcome 1: Hyperkalaemia" data-id="CD007004-fig-0069" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Finerenone versus eplerenone, Outcome 1: Hyperkalaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Finerenone versus eplerenone, Outcome 2: Death" data-id="CD007004-fig-0070" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Finerenone versus eplerenone, Outcome 2: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0071"> <p> <div class="table" id="CD007004-tblf-0030"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>eGFR: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐HF 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone versus eplerenone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At day 90, there was no significant change in eGFR from baseline in finerenone groups (mean change in eGFR range ‐2.4 to 1.3 mL/min/1.73 m<sup>2</sup>) versus eplerenone (mean change in eGFR ‐1.1 mL/min/1.73 m<sup>2</sup>) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Finerenone versus eplerenone, Outcome 3: eGFR: descriptive outcome data</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0071">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Finerenone versus eplerenone, Outcome 4: Doubling serum creatinine" data-id="CD007004-fig-0072" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Finerenone versus eplerenone, Outcome 4: Doubling serum creatinine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0073"> <p> <div class="table" id="CD007004-tblf-0031"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Blood pressure: descriptive outcome data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>ARTS‐HF 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Finerenone versus eplerenone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In patients with worsening heart failure with reduced ejection fraction, there was no difference between the systolic BP in the finerenone groups (LS mean change in systolic BP from baseline range ‐0.8 to ‐2.7 mmHg) compared to eplerenone group (LS mean change in systolic BP from baseline ‐2.4 mmHg) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Finerenone versus eplerenone, Outcome 5: Blood pressure: descriptive outcome data </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0073">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 1: Hyperkalaemia" data-id="CD007004-fig-0074" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 1: Hyperkalaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0075"> <p> <div class="table" id="CD007004-tblf-0032"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Proteinuria</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of outcome</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bianchi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spironolactone, ramipril, irbesartan (intensive group) versus spironolactone, ramipril (conventional group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At month 36, proteinuria was significantly lower in the intensive group (end of study median proteinuria 0.45 g/g Cr, IQR 0.14 to 1.51) compared to conventional group (end of study median proteinuria 1.23 g/g Cr, IQR 0.36 to 3.42) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 2: Proteinuria</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0075">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007004-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 3: eGFR [mL/min/1.73 m²]" data-id="CD007004-fig-0076" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 3: eGFR [mL/min/1.73 m²] </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 4: Systolic BP" data-id="CD007004-fig-0077" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 4: Systolic BP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 5: Diastolic BP" data-id="CD007004-fig-0078" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 5: Diastolic BP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 6: Serum potassium" data-id="CD007004-fig-0079" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 6: Serum potassium</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007004-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/urn:x-wiley:14651858:media:CD007004:CD007004-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 7: Gynaecomastia" data-id="CD007004-fig-0080" src="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_t/tCD007004-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Spironolactone plus ACEi and ARB versus ACEi, Outcome 7: Gynaecomastia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/media/CDSR/CD007004/image_n/nCD007004-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aldosterone antagonists versus placebo or standard care for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus placebo or standard care for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> placebo or standard care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or standard care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.33 to 27.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1,000<br/>(37 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.17<br/>(1.47 to 3.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3001 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1,000<br/>(1 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.10 to 3.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000<br/>(8 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/>(0.26 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1067 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doubling serum creatinine</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>107 per 1,000<br/>(57 to 202) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.30<br/>(0.69 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AKI</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1,000<br/>(31 to 119) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.04<br/>(1.05 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1446 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD was 0.51 lower with aldosterone antagonists (0.82 lower to 0.20 lower) than placebo or standard care </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1193 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>7, 8, 9, 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR (mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 3.00 mL/min/1.73 m² lower with aldosterone antagonists (5.51 lower to 0.49 lower) than placebo or standard care </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1144 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2, 11</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study and complete outcome data in no studies </p> <p><sup>2</sup> Treatment estimate had a wide CI </p> <p><sup>3</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in three studies, blinding of outcome assessment in seven studies, complete outcome data in 11 studies </p> <p><sup>4</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in one study, and complete outcome data in one study </p> <p><sup>5</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in one study, complete outcome data in one study </p> <p><sup>6</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in three studies, complete outcome data in one study </p> <p><sup>7</sup> Evidence quality was downgraded because of suspected small study effects from asymmetry on inverted funnel plot </p> <p><sup>8</sup>Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in seven studies, complete outcome data in nine studies </p> <p><sup>9</sup> There was significant heterogeneity between studies </p> <p><sup>10</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> <p><sup>11</sup> Evidence quality was downgraded because of study risks of bias. Allocation concealment in one study, blinding of outcome assessment in four studies, complete outcome data in six studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aldosterone antagonists versus placebo or standard care for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aldosterone antagonists versus diuretics for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus diuretics for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> diuretics </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with diuretics</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD was 1.59 lower (3.8 lower to 0.62 higher) with aldosterone antagonists than diuretics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1, 2, 3, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean eGFR was 2 mL/min/1.73 m² higher with aldosterone antagonists (26.31 lower to 30.31 higher) than diuretics </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded due to study risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete data in one study </p> <p><sup>2</sup> There was significant heterogeneity between the studies </p> <p><sup>3</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> <p><sup>4</sup> Treatment estimate had a wide confidence interval </p> <p><sup>5</sup> Single study with unclear allocation concealment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Aldosterone antagonists versus diuretics for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Aldosterone antagonists versus calcium channel blockers for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonists versus calcium channel blocker for proteinuric CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric CKD<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> calcium channel blocker </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with calcium channel blocker</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not to be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study with unclear allocation concealment </p> <p><sup>2</sup> Evidence quality was downgraded because proteinuria is a surrogate outcome for CKD progression </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Aldosterone antagonists versus calcium channel blockers for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> ACEi or ACEi plus ARB </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ACEi or ACEi plus ARB</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000<br/>(24 to 146) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.62<br/>(0.66 to 3.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3, 4, 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR</p> <p>(mL/min/1.73 m²)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>6, 7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACEi:</b> angiotensin‐converting enzyme inhibitors; <b>ARB:</b> angiotensin receptor blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Evidence quality was downgraded due to risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete outcome data in one study </p> <p><sup>2</sup> Treatment estimates had wide confidence intervals </p> <p><sup>3</sup> Evidence quality was downgraded due to risks of bias. Allocation concealment in no studies, blinding of outcome assessment in one study, complete outcome data in two studies </p> <p><sup>4</sup> Evidence quality was downgraded as proteinuria is a surrogate outcome for CKD progression </p> <p><sup>5</sup> Raw data was not available in studies to allow pooling of treatment estimates </p> <p><sup>6</sup> Single study with unclear allocation concealment </p> <p><sup>7</sup> Insufficient studies to inform precision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Aldosterone antagonists versus ACEi or ACEi plus ARB for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> aldosterone antagonist<br/><b>Comparison:</b> nitrate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with nitrate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with aldosterone antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doubling serum creatinine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteinuria</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data could not be meta‐analysed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study with unclear allocation concealment and unclear blinding of outcome assessment </p> <p><sup>2</sup> Evidence quality was downgraded as proteinuria is a surrogate outcome for CKD progression </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Aldosterone antagonist versus nitrate for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007004-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> proteinuric chronic kidney disease<br/><b>Intervention:</b> non‐steroidal mineralocorticoid receptor antagonist<br/><b>Comparison:</b> selective aldosterone antagonist </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with selective aldosterone antagonist</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐steroidal mineralocorticoid receptor antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/>(21 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.45 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1023 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/>(11 to 56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.31 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1055 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doubling serum creatinine</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/834</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/221**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80<br/>(0.03 to 19.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1055 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proteinuria</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>eGFR</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>** Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the non‐steroidal mineralocorticoid receptor antagonist group<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>AKI:</b> acute kidney injury; <b>eGFR:</b> estimated glomerular filtration rate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Single study </p> <p><sup>2</sup> Treatment estimate had a wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Non‐steroidal mineralocorticoid receptor antagonist versus selective aldosterone antagonist for proteinuric chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/full#CD007004-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aldosterone antagonist versus placebo/standard care (all studies)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Kidney failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.33, 27.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.47, 3.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.20, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [1.35, 8.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.14 [0.82, 46.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Subgroup analysis: hyperkalaemia ‐ number of RAS inhibitors used <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.42, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Aldosterone antagonist plus 1 RAS inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.28, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Aldosterone antagonist plus 2 RAS inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [1.12, 16.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Hyperkalaemia data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.10, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.03, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.12, 68.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.33, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.57, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.11, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.12, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐0.82, ‐0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.64, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.57, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.49, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Proteinuria: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Proteinuria data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 eGFR [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐5.51, ‐0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.43 [‐8.35, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.26 [‐8.69, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐5.85, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 eGFR: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 eGFR data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Doubling serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.98 [‐8.22, ‐1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐1.80, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.35 [‐5.06, ‐1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.07 [‐29.27, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐2.82, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.95, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐2.86, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.52 [‐10.75, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Blood pressure: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Blood pressure data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.10, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.14, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.21, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Potassium: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.99, 3.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.26, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.3 Diabetes not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.08, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Gynaecomastia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.14 [1.14, 23.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.02 [1.08, 33.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Subgroup analysis: proteinuria ‐ duration of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.83, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.54, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 At least 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.68, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Subgroup analysis: systolic BP ‐ duration of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.98 [‐8.22, ‐1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.65 [‐10.96, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 At least 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.62 [‐6.09, ‐1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Subgroup analysis: diastolic BP ‐ duration of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐2.81, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐3.71, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 At least 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐2.86, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Subgroup analysis: serum potassium ‐ duration of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.13, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 Less than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.10, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 At least 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 0.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aldosterone antagonist versus placebo/standard care (all studies)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐3.80, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proteinuria: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proteinuria data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 eGFR [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 GFR: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 eGFR data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐3.52, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.79 [‐14.36, 6.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Blood pressure: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Blood pressure data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.17, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Potassium: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Potassium data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aldosterone antagonist plus RAS inhibitor versus other diuretic plus RAS inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Spironolactone versus calcium channel blockers</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proteinuria: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Spironolactone versus calcium channel blockers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Eplerenone versus ACEi</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Hyperkalaemia data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Proteinuria data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Eplerenone versus ACEi</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Eplerenone versus ACEi plus ARB</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Hyperkalaemia data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Proteinuria data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Eplerenone versus ACEi plus ARB</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.66, 3.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Proteinuria: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Proteinuria data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 eGFR: data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Blood pressure: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Blood pressure data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Serum potassium: data from cross‐over studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Proteinuria: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Systolic BP: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Eplerenone plus ACEi or ARB (or both) versus ACEi or ARB (or both) plus nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Finerenone versus eplerenone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 eGFR: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Doubling serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Blood pressure: descriptive outcome data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Finerenone versus eplerenone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007004-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Spironolactone plus ACEi and ARB versus ACEi</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 eGFR [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Gynaecomastia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Spironolactone plus ACEi and ARB versus ACEi</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007004.pub4/references#CD007004-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007004.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007004-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007004-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007004-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD007004-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007004-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007004-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007004\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007004\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007004\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007004\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007004\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007004.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007004.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007004.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007004.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007004.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727988250"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007004.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727988254"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007004.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb97c0875937f',t:'MTc0MDcyNzk4OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 